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Abstract
Children who are unfortunate enough to develop cancer are now able to achieve
long-term survival as a consequence of improved treatment. However, a significant
proportion of these children experience a high level of morbidity and their quality of
life is of increasing concern. This morbidity relates not only to the primary disease,
but also to the effects of the treatment they have received. An important
consequence of radiotherapy and chemotherapy is the long-term effect on the
endocrine system. Endocrine deficits can occur as a result of target organ damage
to the thyroid, gonad or adrenal gland by both radiotherapy and chemotherapy, as
well as damage to the hypothalamo-pituitary (HP) axis. While most endocrine deficit
can be pre-empted by regular surveillance, the detection of secondary
adrenocortical insufficiency (SAI) poses a particular problem. The symptoms of SAI
(tiredness, lethargy, etc.) are non-specific, and are very similar to those that can
result from anti-cancer therapy. Moreover, existing tests of adrenal function are
difficult to interpret, and may not be diagnostic in children with mild to moderate
degrees of SAI. It is in the child's interest for SAI to be promptly diagnosed and
steroid replacement instigated. Correct diagnosis is essential as steroid therapy can
have an adverse effect on growth and may cause weight gain.
This thesis aims to address the challenge of diagnosing SAI in long-term survivors
of childhood cancer. The study group included patients who had received
radiotherapy for brain tumours, total body irradiation as part of conditioning
treatment for bone marrow transplantation, and patients with leukaemia who had
relapsed and had received cranial irradiation as part of their treatment.
Sensitive assays of steroids in saliva (Cortisol, 17-hydroxyprogesterone, and
androstenedione) have been developed using radioimmunoassays with
microencapsulated antibody. A reference range of these steroids in saliva has been
determined using a control population of schoolchildren enabling salivary steroid
profiles to be used in the assessment and monitoring of adrenocortical function in
survivors of childhood cancer. These results have been compared with standard
tests of adrenocortical function.
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This thesis has shown that the use of salivary steroid profiles can be useful in the
diagnosis of SAI. We have also shown that SAI is not as prevalent as has been
reported in previous studies.
The methods developed in this study are simple and non-invasive and of clinical use
in the ongoing assessment and monitoring of adrenal function in conjunction with





ALL Acute lymphoblastic leukaemia
AML Acute myeloid leukaemia
AVP Arginine vasopressin
BMT Bone marrow transplantation
CAH Congenital adrenal hyperplasia
cGy Centigray
CNS Central nervous system





GHRH Growth hormone releasing hormone
GnRH Gonadotrophin releasing hormone
Gy Gray (unit of radiotherapy dose)
HP Hypothalamo-pituitary
HPA Hypothalamo-pituitary-adrenal
IGF-1 Insulin-like growth factor 1
ITT Insulin tolerance test
LHRH Leutinising hormone releasing hormone
PAM Permeable antibody containing microcapsules
POMC Pro-opiomelanocortin
RHSC Royal hospital for sick children
RIA Radioimmunoassay
SAI Secondary adrenocortical insufficiency
SHBG Sex hormone binding globulin
TBI Total body irradiation
TRH Thyroid releasing hormone
TSH Thyroid stimulating hormone
UK United Kingdom
UKCCSG United Kingdom Childhood Cancer Surveillance Group
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1 The Effects of Treatment in the
Development of Endocrine
Dysfunction in Childhood Cancer
Survivors
1.1 Introduction
Children who are unfortunate enough to develop cancer are now able to achieve
long-term survival. However, with prolonged survival of these patients, late
complications of their treatment are a recognised cause of morbidity and their
quality of life is of increasing concern. Morbidity in these long-term survivors relates
not only to the primary disease itself, but also to the effects of the various types of
treatment (Byrd 1983; Deeg et al 1984; Ochs & Mulhern 1988; Sklar & Nesbit 1981).
An important consequence of chemotherapy, and in particular, radiotherapy, is the
long-term effect on the endocrine system. There are numerous reports and studies
in the current literature of various endocrine deficits that occur as a result of
treatment of childhood cancers (Brown et al 1983; Oberfield et al 1986; Ogilvy-
Stuart et al 1992; Ogilvy-Stuart et al 1994; Oliff et al 1979; Sanders et al 1986;
Shalet et al 1975; Shalet et al 1976a; Shalet et al 1988).
Endocrine deficits can occur as a result of target organ damage to the thyroid,
gonad or adrenal gland by both radiotherapy and chemotherapy. (Leiper et al
1987a; Littley et al 1991; Oberfield, Allen, Pollack, New, & Levine 1986; Ogilvy-
Stuart, Clark, Wallace, Gibson, Stevens, Shalet, & Donaldson 1992). In addition,
they may result from damage to the hypothalamo-pituitary (HP) axis (Brown, Lee,
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Eden, Bullimore, & Savage 1983; Littley et al 1989; Oberfield, Allen, Pollack, New, &
Levine 1986; Ogilvy-Stuart, Clayton, & Shalet 1994; Shalet, Beardwell, Morris-
Jones, & Pearson 1975; Shalet et al 1976b; Shalet, Clayton, & Price 1988). The
original disease process may also cause endocrine deficit, depending on the
anatomical site (e.g. a hypothalamic tumour, or a tumour encroaching on the HP
territory).
While most endocrine deficits can be pre-empted by regular surveillance, the
detection of secondary adrenocortical insufficiency (SAI) poses a particular problem.
This is because the symptoms of SAI (tiredness, lethargy, etc.) are non-specific, and
may be difficult to differentiate from symptoms which can occur as a consequence of
anti-cancer therapy. Moreover, existing tests of adrenal function are difficult to
interpret, and may not be diagnostic in children with mild to moderate degrees of
adrenocortical insufficiency. For example, in SAI, the Cortisol response to standard
adrenocorticotrophic hormone (ACTH) stimulation may be normal (Cunningham et al
1983).
Incomplete or partial SAI may result in years of poor general health with lack of
energy especially on rising, tiredness, lethargy, and difficulty in shaking off trivial
inter-current illness (Leshin 1982; Mansell et al 1993). Clearly, it is in the child's
interest for adrenocortical insufficiency to be promptly diagnosed and steroid
replacement instigated. Correct diagnosis is essential as steroid therapy can have
an adverse effect on growth and may cause weight gain. The unnecessary use of
hydrocortisone in these patients should therefore be avoided.
This study attempts to address the problem of diagnosing SAI in long-term survivors
of childhood cancer. In particular, the main aim is to develop and evaluate a
sensitive method of diagnosing or screening for SAI in a manner that involves
minimal hazard and upheaval to the child. If successful, such a method should
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allow an accurate assessment of the incidence of SAI, and facilitate the monitoring
of at-risk children.
Although relatively rare in childhood, cancer is a significant cause of death. By the
age of 15 years approximately 1 child in 650 is affected by malignant disease
(UKCCSG 1996) (Figure 1.1). Children can be affected by a variety of
malignancies. Recent data demonstrate that over one third are leukaemias, and
almost one quarter originates in brain and spinal cord (Stiller 1992) (Figure 1.2).
Cancer survival rates are improving. In a study based on figures obtained from the
Manchester Children's Tumour Registry, survival rates in various childhood cancers
were compared from three decades: 1954 - 1963, 1964 - 1973, and 1974 - 1983
(Birch et al 1988). For all cancers, there was a more than two-fold increase in
survival (from 21 to 49%) between the first and third decades. There was a more
than 23-fold improvement in leukaemia survival (2 to 47%), and a six-fold
improvement in germ cell tumour survival. Medulloblastoma survival improved from
25% to 41%. Similar results have also been reported in other studies (Schellong
1985).
Improvements in cancer treatment have increased the survival rates for the majority
of childhood cancers, especially leukaemias (Figure 1.3).
Survival rates in childhood cancer depend on the type and the extent of disease at
presentation; this in turn determines the treatment regimen for the particular child.
The improved survival in the leukaemias has been largely the result of the
development of effective chemotherapy protocols using multiple agents. Improved
radiotherapy techniques for solid tumours, has helped to minimise the development
of side effects, with maximal tumour resolution. Some of the improvements in
survival can be related to centralisation of treatments for all cancers in specialist
centres (Stiller 1988).
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What constitutes cure for childhood cancer? In the Manchester study, only 1% of
patients died from recurrence more than 10 years after diagnosis. Disease free
survival 10 years from treatment may therefore be regarded as "cure" of the primary
cancer. With current survival figures, it has been estimated that by the year 2000, 1
in 1000 children will be survivors of childhood cancer (Birch, Marsden, Morris-Jones,
Pearson, & Blair 1988).
With the use of powerful chemotherapeutic agents and improved radiotherapy, the
price of survival may be an increase in the prevalence of late effects of cancer
therapy, including endocrine, psychological, intellectual, cardiac and renal effects.
Endocrine late effects have been related to radiotherapy particularly affecting the
HP region, the thyroid, and gonads, and may not become manifest for years after
treatment. It was believed that the site of radiation damage was the pituitary gland,
but more recent evidence indicates that it is the hypothalamus that is principally
affected (Stiller 1992). Chemotherapy is increasingly recognised as having an
important role in predisposing to endocrine late-effects.
Most endocrine late effects relate to the treatment of leukaemias and brain tumours
that has involved radiotherapy and/or chemotherapy to the HP axes (growth,
gonads, thyroid and adrenal).
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1.1.1 The Childhood Leukaemias: Effects on Growth and
Endocrine Function
The treatment of childhood leukaemia has been continually modified and improved
to reduce adverse effects and improve the chances of survival. The Medical
Research Council has in the context of formal clinical trials established treatment for
most children in the United Kingdom (UK) (UKCCSG 1995).
Survival from Acute lymphoblastic leukaemia (ALL) has increased dramatically over
the past thirty years (Birch, Marsden, Morris-Jones, Pearson, & Blair 1988) (Figure
1.3). A study in 1989 reported an overall first remission rate of 94%, and an event
free survival rate at 8 years of 44% (Van Eys et al 1989). These figures have been
echoed in other studies (Birch, Marsden, Morris-Jones, Pearson, & Blair 1988).
1.1.1.1 Chemotherapy and Cranial Prophylaxis
ALL treatment uses certain chemotherapeutic agents in carefully calculated
combinations. They have included maintenance treatment with 6-mercaptopurine
and methotrexate with regular pulses of prednisolone, vincristine and daunorubicin,
as well as pulses of cytarabine, etoposide, thioguanine and asparaginase. From
1972, low dose cranial irradiation (18 to 24 Gy) has been used in all protocols as
prophylaxis against central nervous system involvement with leukaemia (Aur et al
1972). The use of cranial irradiation has greatly improved the prognosis of children
treated for ALL (Hustu et al 1973). More recently, in an attempt to reduce the
cognitive, psychological and growth sequelae of cranial irradiation, particularly in the
younger child, the MRC UKALL XI protocol has been instituted to assess the
benefits of either high dose intravenous or intrathecal methotrexate in preference to
cranial irradiation (Byrd 1983; Ochs & Mulhern 1988). This protocol resulted from
evidence presented by the American Children's Cancer Study Group that showed
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that children in a 'good risk' group could be treated without cranial irradiation if long-
term intrathecal methotrexate was given (American CCSG 1982; Littman et al 1987).
Endocrine deficits in ALL include disturbance of GH secretion, onset of early
puberty, body disproportion and altered body composition. Factors causing these
problems include cranial irradiation, chemotherapy, and preparation for bone
marrow transplantation. The most important cause of endocrine deficit is cranial
irradiation. In general, a lower dose of radiotherapy is employed in cranial
prophylaxis for ALL in order to prevent central nervous system (CNS) seeding,
compared with radiotherapy of brain tumours, in which much higher doses are used.
1.1.1.1.1 Growth Hormone deficiency
In children treated with cranial irradiation, one of the most important late effects is
that on growth and growth hormone. It has been estimated that 25 to 50% of ALL
survivors have reduced GH secretion; moreover, the predicted final height for these
children is seldom attained (Byrd 1983; Ochs & Mulhern 1988; Oliff, Bode, Bercu, Di
Chiro, Graves, & Poplack 1979; Romshe et al 1984). Understandably, this is the
most frequently studied abnormality of endocrine function following cancer
treatment. Several studies have produced conflicting results of effects on growth as
a result of this 'low dose' radiotherapy. In 1988, a study by Clayton et al showed
that there was a reduction in growth in children who had received 1800 to 2500cGY
cranial irradiation, up to four years after treatment (Clayton et al 1988). This was
also found by other workers (Starceski et al 1987; Wells et al 1983). However,
Shalet et al found that children treated for ALL with cranial or craniospinal irradiation
(2400 or 2500cGy) were significantly smaller than a control group, and had a normal
growth pattern despite showing a diminished growth hormone response to arginine
and hypoglycaemia (Shalet et al 1979). Other workers have also shown a normal
growth pattern in this group of children, but GH secretion was either normal or
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abnormal (Shalet et al 1977; Swift et al 1978; Verzossa et al 1976). In 1986, the
results of a study was reported in which 4 out of 14 children in remission of their ALL
for at least 3 years had biochemical evidence of GH deficiency (Asa et al 1986).
None of the children had any other detectable endocrine abnormality.
In 1984, reduced pulsatile GH secretion was shown to occur over 24 hours in 8
long-term ALL survivors who were treated with 2400cGy cranial irradiation 4 to 10
years previously (Blatt et al 1984). The area under the curve for growth hormone
profiles was reduced in these patients compared to a control population, as was
growth hormone output through the night and during the day. The frequency and
amplitude of growth hormone pulses were also reduced. In this group of patients, 3
had a normal GH response to hypoglycaemia, two had a borderline response.
In 1977, in a study of 77 children with ALL treated with chemotherapy and 2400 cGy
cranial irradiation (given in 15 fractions over 3 weeks) 3 to 9.5 years previously,
growth was shown to be reduced, demonstrated by a reduction in the standard
deviation score over time from diagnosis (Kirk et al 1987). A much higher
prevalence of growth hormone deficiency was found (30 of 42 children tested) than
had been reported in other studies. Pulsatile growth hormone secretion was also
reduced.
1.1.1.1.2 Thyroid Dysfunction
Abnormalities of thyroid function are well described in children treated with cranial or
craniospinal irradiation for ALL. There is a very low risk of developing thyroid
deficiency, with a reported prevalence of 0.2% (Robison et al 1985). In this study,
however, 10% of children had a raised TSH level with normal thyroxine levels
suggestive of a compensated euthyroid state. The majority of these children had
subsequent normal TSH concentrations. All of them were clinically euthyroid.
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7.7.1.1.3 Gonadal and Pubertal Dysfunction
Pubertal dysfunction, in particular, early or precocious puberty, is a recognised
consequence of low dose cranial irradiation in ALL prophylaxis. It is associated with
a high prevalence of earlier age of pubertal onset and menarche in girls (Leiper,
Stanhope, & Kitching 1987a; Quigley et al 1989). Early puberty has also been
documented in boys surviving ALL, although the prevalence is similar to the normal
population.
1.1.1.2 Bone Marrow Transplantation
Bone marrow transplantation (BMT) in combination with high dose chemotherapy is
used with success in an increasing number of children with malignant
haematological conditions such as ALL and acute myeloblasts leukaemia (AML).
BMT is also used in the treatment of stage IV neuroblastoma. BMT preparatory
regimens include the use of chemotherapeutic agents such as cyclophosphamide
and cytosine arabinoside, together with total body irradiation (TBI) in the treatment
of malignant disease. In non-malignant conditions BMT is a successful method of
treatment used without TBI. The TBI dose has in the past been given as a single
dose, or in a dose, which is fractionated. Latest regimens now use only fractionated
TBI doses, as single dose TBI results in a greater incidence of side effects (Brauner
et al 1993; Sanders, Pritchard, Mahoney, Amos, Buckner, Witherspoon, Deeg,
Doney, Sullivan, Appelbaum, Storb, & Thomas 1986). Children with non-malignant
disease, such as aplastic anaemia, are also treated with BMT, but TBI and
chemotherapy are not used in BMT preparation.
BMT preparative regimens, particularly the use of single dose TBI, are a potent
cause of endocrine dysfunction (Deeg, Storb, & Thomas 1984). Pituitary
dysfunction is well recognised, with a high incidence of GH deficiency (up to 70% of
survivors) (Sanders, Pritchard, Mahoney, Amos, Buckner, Witherspoon, Deeg,
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Doney, Sullivan, Appelbaum, Storb, & Thomas 1986). There is also a high
incidence of primary thyroid dysfunction (39%) and primary gonadal failure (68%).
In postpubertal children, gonadal failure was uniformly observed. The likelihood of
gonadal and thyroid dysfunction was not related to previous cranial irradiation in
children who had received single dose TBI (Leiper et al 1987b).
Fractionated TBI has a lower incidence of GH deficiency in adults (Littley, Shalet,
Morgenstern, & Deakin 1991) but similar rates of thyroid dysfunction. Other studies
have confirmed a high incidence of GH deficiency together with gonadal and thyroid
dysfunction in children (Papadimitriou et al 1991). However, GH deficiency is felt by
some researchers to be the result of previous cranial irradiation; the total dose of
cranial irradiation received is therefore important (Brauner, Fontoura, Zucker,
Devergie, Souberbielle, Prevot-Saucet, Michon, Gluckman, Griscelli, Fischer, &
Rappaport 1993). Other studies have not been able to substantiate this finding
(Shalet, Clayton, & Price 1988).
Fractionated TBI is now known to produce fewer endocrine deficits, although the
endocrine morbidity it causes still remains significant (Ogilvy-Stuart, Clark, Wallace,
Gibson, Stevens, Shalet, & Donaldson 1992).
1.1.2 Brain Tumours: Effects on Growth and Endocrine
Function
Intracranial tumours are the second most common malignancy of childhood, after
leukaemia. They comprise 25% of childhood malignancies (Birch, Marsden, Morris-
Jones, Pearson, & Blair 1988) (Figure 1.2). Up to 25% of brain tumours are
medulloblastomas. The five-year survival rate for brain tumour patients is continuing
to improve, but remains relatively low; for patients with medulloblastoma the survival
rate is approximately 50% (UKCCSG Figures).
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Treatment of brain tumours in children generally consists of high doses of cranial
irradiation (commonly in excess of 35 Gy) together with surgery, and occasionally
chemotherapy. Cranial irradiation involves treatment to the whole brain, as well as
to the tumour site. In the treatment of medulloblastoma, the spinal cord is also
irradiated.
Despite improvements in survival for these children, the late effects of treatment are
high, especially the endocrine deficits (Brown, Lee, Eden, Bullimore, & Savage
1983; Oberfield, Allen, Pollack, New, & Levine 1986). GH deficiency is common
(Brown, Lee, Eden, Bullimore, & Savage 1983; Shalet, Beardwell, Morris-Jones, &
Pearson 1975; Shalet, Beardwell, Pearson, & Morris-Jones 1976b; Sklar & Nesbit
1981; Woodside et al 1991). In general, the higher the dose of irradiation the more
likely and the earlier the onset of growth hormone deficiency.
In 1975, Shalet et al found an abnormal growth hormone response to
hypoglycaemia in 10 out of 27 children treated for intracranial tumours out with the
HP axis (Shalet, Beardwell, Morris-Jones, & Pearson 1975). The TSH response to
TRH was also abnormal in the growth hormone deficient children. In 1976, the same
group subsequently found that there was a significant inverse correlation between
radiation dose and peak growth hormone response to hypoglycaemia in children
treated with high dose cranial irradiation (greater than 2900cGy) for brain tumours
out with the HP axis (Shalet, Beardwell, Pearson, & Morris-Jones 1976b). It was
calculated that the threshold dose for growth hormone deficiency in these children
was 2900cGy, although data was not available in the dose range 2500 - 2900cGy.
In 1986, evidence was presented which showed that GH deficiency in children
occurred if they were treated with at least 2400cGy cranial irradiation (Ahmed et al
1986).
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A retrospective study by Winter et al in 1985 (Winter & Green 1985) found that in 5
patients treated with high dose cranial irradiation who were growth hormone
deficient, the growth response to growth hormone therapy was blunted and skeletal
maturation was augmented. However, some of the children had had treatment for
pituitary-hypothalamic lesions, which themselves may interfere with growth hormone
secretion.
In 1983, a study found abnormal growth in all 13 children with medulloblastoma who
were studied (Brown, Lee, Eden, Bullimore, & Savage 1983). Nine patients had an
abnormal GH response to hypoglycaemia. In a similar study, 14 out of 19 children
with medulloblastoma had decreased growth rates, but 5 children had abnormal GH
response (Oberfield, Allen, Pollack, New, & Levine 1986).
In addition to growth hormone deficiency, thyroid and pubertal dysfunction are well
documented. In medulloblastoma patients treated with high dose cranial irradiation,
a high prevalence of elevated TSH levels were found, with a high incidence of
compensated hypothyroidism in these patients (Oberfield, Allen, Pollack, New, &
Levine 1986). One case of each of primary and tertiary hypothyroidism was found in
the group of 22 patients studied.
Onset of puberty occurs at an earlier age in both treated girls and boys (Brauner et
al 1984; Brauner & Rappaport 1990; Moris 1981). The younger the child at
irradiation, the earlier the age of onset of puberty (Ogilvy-Stuart, Clayton, & Shalet
1994).
1.1.3 Radiotherapy and its Effects on the Hypothalamo-
Pituitary Axis
Cranial irradiation is an important part of treatment of childhood malignancy. The
dose used, the number of fractions, the radiation field and the lengths of treatment
depend on the nature of the initial disease and the reason for cranial irradiation (e.g.
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prophylaxis or tumour destruction). These factors in turn influence the likelihood of
late endocrine effects resulting from anterior pituitary hormone deficit, (see Table
1.1, 1.2) The magnitude of dose of radiotherapy given is dependent on the type of
cancer (see Table 1.3). The degree of anterior pituitary hormone deficit is related to
the radiation dose received by the hypothalamo-pituitary axis, higher doses
producing panhypopituitarism, whereas lower doses cause isolated GH deficiency
(Shalet, Clayton, & Price 1988).
In 1989, a Manchester group (Littley, Shalet, Beardwell, Ahmed, Applegate, &
Sutton 1989) studied the development of anterior pituitary deficiencies in adults
treated with radiotherapy for pituitary tumours. The majority had had surgery prior to
radiotherapy.
A high incidence of anterior pituitary hormone deficiencies were found in this group,
with all patients growth hormone deficient after 5 years, 91% gonadotrophin
deficient, 77% corticotropin deficient, and 42% thyrotrophin deficient. The
prevalence increased with time (Figure 1.4). The sequence of development of
hormone deficiencies was found to occur most commonly in that order. This study
has been used by many workers to state the rate of onset of endocrine deficiencies
in children who had received cranial irradiation but who did not have intrinsic
pituitary disease.
The effects of varying doses of cranial irradiation on endocrine function in children
have been studied by several groups who have tended to study effects on growth
hormone production. The development of endocrine deficit is related not only to the
dose received but also to the interval. Thus, Jenkins et al reported that radiotherapy
in doses of 3.5 to 5.0 Gy in patients with pituitary tumours was generally well
tolerated with little effect on residual pituitary function (Jenkins et al 1972).
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Romshe et al studied a group of 9 children who had received cranial irradiation of at
least 1500 cGy 2 years or more prior to commencement of the study (Romshe, Zipf,
Miser, Miser, Sotos, & Newton 1984). They found significant GH deficiency in this
group, with abnormal growth hormone response to hypoglycaemia, and abnormal
GH profile of GH pulsatility, but a normal response to arginine and L-dopa. However,
the patient group was heterogeneous, with two patients treated for
medulloblastoma.
Cranial irradiation causes damage to the hypothalamus and the pituitary with the
hypothalamus being more vulnerable. In 1982 a discordant response to arginine and
insulin hypoglycaemia was demonstrated in the cranial irradiated monkey (Chrousos
et al 1982). Chrousos also demonstrated severe blunting of physiological GH
secretion despite a normal response to pharmacological stimulus. Similar results
have been obtained in humans (Dickinson et al 1978; Shalet, Price, & Beardwell
1979). It has also been shown that despite a subnormal GH response to
hypoglycaemia, patients responded normally to GHRH (Ahmed & Shalet 1984;
Lannering & Albertsson-Wiklund 1987). A study in 1986 (Lam et al 1986) showed
evidence of hypothalamic dysfunction in patients treated for nasopharyngeal
carcinoma, with raised prolactin levels, normal response to GnRH with subnormal
gonadal function, normal but delayed TSH response to TRH in the presence of
subnormal thyroid function, and normal ACTH response to CRH in the presence of
subnormal adrenocortical function.
35
Site of initial disease
Dose of Radiotherapy
Site of radiotherapy
Age at commencement of radiation treatment
Number of years from treatment
Chemotherapeutic agents used
Table 1.1. Factors affecting likelihood of developing
endocrine deficit in children treated for cancer
Type of treatment Radiation dose (Gy) Endocrine deficit
Cranial irradiation 18 to 24
Growth hormone insufficiency; impaired growth
Early puberty; Precocious puberty
Growth hormone deficiency
Early puberty; Precocious puberty
Cranial irradiation >24 Gonadotrophin deficiency
Adrenocorticotrophin deficiency
Secondary hypothyroidism (uncommon)
Anterior pituitary hormone deficiencies
Craniospinal irradiation >30 Primary hypothyroidism
Poor spinal growth
Testicular irradiation 6
Gonadal failure - Leydig cell damage
Infertility
Primary hypothyroidism
Total body irradiation 12 to 14 Primary gonadal failure (male and female)
Growth hormone deficiency
Reduced bone growth
Chemotherapy Primary gonadal damage
Compensated hypothyroidism
Table 1.2. The potential effect of chemotherapy and varying doses of radiotherapy on
the development of endocrine deficit.
(Shalet et al 1979; Swift et al 1976; Asa et al 1986; Blatt et al 1984; Leiper et al 1987; Quigley et al 1989;
Sanders et al 1986; Brown et al 1983; Shalet et al 1975; Sklar et al 1981; Woodside et al 1991; Ahmed et al
1986; Ogilvy-Stuart et al 1995)





ALL initial presentation Cranial/craniospinal 1800 1800
ALL CNS relapse Cranial 600 - 2400 600 - 2400








Optic Glioma Cranial 5000 5000
Germ cell Tumour Craniospinal 3500 3500
Table 1.3. Standard irradiation doses used in the treatment of
childhood malignancy
years
Figure 1.4. Likelihood of developing anterior
pituitary hormone deficiencies with time. (Littley et al)
(Derived from adults with pituitary tumours who received between
37 to 42 Gy external radiotherapy in 15 or 16 fractions over 20 to 22
days).
(Permission granted from Oxford University Press for reproduction of this Figure
01/02/04)
1.1.4 Chemotherapy and its Effects on the Hypothalamo-
Pituitary Axis
Endocrine dysfunction as a consequence of chemotherapy is difficult to ascertain,
as the use of chemotherapy along with radiotherapy in malignant disease is
universal. There is in-vitro evidence to suggest that chemotherapy affects the
epiphyseal growth plate, (Moris 1981) but little conclusive evidence to state that
chemotherapy has a definite effect in vivo.
Evidence is accumulating that there is a cumulative effect of both radiotherapy
and chemotherapy on growth, and probably also on gonadal function (Ogilvy-Stuart
& Shalet 1995).
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2 Assessment of the Hypothalamo-
Pituitary-Adrenocortical Axis
2.1 Overview of the Hypothalamo-Pituitary-Adrenal
Axis
The hypothalamo-pituitary-adrenal (HPA) axis regulates the production of
glucocorticoid, principally Cortisol, and to a much lesser extent, mineralocorticoid,
mainly aldosterone. Corticotrophin releasing hormone (CRH) is produced in the
paraventricular nucleus of the hypothalamus and acts synergistically with arginine-
vasopressin (AVP) to stimulate ACTH release from the corticotroph cells of the
anterior pituitary gland. This in turn stimulates steroid synthesis and release from
the adrenal cortex. Glucocorticoids released from the adrenal cortex have an
important role to play in controlling the body's metabolic processes.
2.1.1 Control of Glucocorticoid Release
Harris and Green in 1947, proposed that hypothalamic release of a humoral
signal occurred in response to stress (Green & Harris 1947). It was not until 1955
when Guillemin and Rosenberg, and Saffran and colleagues independently
demonstrated CRH-like activity in hypothalamic extracts (Guillemin & Rosenberg
1955; Saffran et al 1955). This was the first hypophysiotrophic activity to be seen.
The chemical identity of CRH was not established until 1981 (Vale etal 1981).
Ovine CRH was subsequently synthesised and shown to stimulate pituitary ACTH
secretion and release (Vale et al 1983).
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Circadian ACTH secretion is believed to be controlled by several factors,
including CRH and AVP stimulation. Light is thought to be one of the most important
factors in controlling the circadian rhythm (Moore-Ede et al 1983; Orth et al 1979).
However, stress-mediated release of ACTH may occur in synergism with AVP,
CRH, catecholamines and other secretagogues whose release is initiated by the
higher centres in the brain (Antoni 1986; Axelrod & Reisine 1984; Feek et al 1983;
Rivier & Vale 1983). CRH neurones are in turn regulated by specific hypothalamic
neurotransmitters such as serotonin, acetylcholine and noradrenaline. It is felt that
these play a significant role in the control of both circadian and stress-mediated
release of CRH (Calogero et al 1988; Jones et al 1976).
CRH is released from the hypothalamus into the portal circulation and
stimulates the release of pro-opiomelanocortin (POMC) through an adenylate
cyclase-mediated process. The control of CRH release is by a negative feedback
loop with Cortisol.
CRH stimulated release of ACTH is one of three regulatory systems for ACTH
secretion; there is also a closed loop negative feedback system responding to
Cortisol, and an open-loop neuronal system channelling stress stimuli (Jones &
Gillham 1988).
ACTH is the main regulator of adrenal glucocorticoid secretion and may be the
main regulator of adrenal androgen secretion. However, an adrenal androgen-
stimulating factor has been postulated but not yet isolated (Cunningham & McKenna
1994). ACTH seems to have a minor role in mineralocorticoid secretion.
ACTH is released in an episodic, pulsatile manner that results in a similar
pulsatile release of Cortisol. The normal diurnal rhythm results from pulsatile release
of ACTH of varying amplitude. The pulses increase in amplitude, reaching a
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maximum in the last few hours before and the hour after wakening. These then
become smaller in amplitude throughout the day, becoming minimal in the evening
(Moore-Ede, Czeisler, & Richardson 1983).
ACTH acts through specific high affinity cell membrane receptors in the adrenal
cortex. ACTH activates adenylate cyclase, resulting in cyclic AMP accumulation in
the adrenocortical cells, increasing protein kinase A activity. This results in Cortisol
synthesis and secretion (Simpson & Waterman 1988).
A number of factors affect CRH and ACTH release. The circadian rhythm is
generated by an endogenous pacemaker located in the suprachiasmatic nucleus of
the hypothalamus. The timing of the rhythm is synchronised with the normal daily
pattern of darkness and light, which normally reflects the sleep-wake pattern. In the
absence of darkness and light as cues (e.g. in blind people), the circadian rhythm
has a 24.5 to 25 hour period (Orth, Besser, & King 1979). The exact mechanism for
this circadian rhythm is unknown. It is felt that CRH has some role to play, but other
factors are involved.
As well as the diurnal rhythm, which governs HPA function, stress (both physical
and psychological) has a potent effect on stimulating the HPA axis. Stress is a
poorly defined term, which includes severe events such as trauma, burns, illness,
major surgery, hypotension and collapse, and everyday experiences like anxiety,
anticipation and mental tasks. The way in which stress exerts its effects on ACTH
secretion is unknown. It appears to act via a central pathway, stimulating the
hypothalamus to release CRH and AVP, which in turn stimulate ACTH release. CRH
may also be directly released by pyrogen, and possibly also by interleukins one and
six released by endotoxin. Interleukin two may stimulate ACTH release both directly




Figure 1.5. Diagrammatic representation of the
Hypothalamo-Pituitary-Adrenal Axis.
2.2 The Adrenal Cortex: Structure and Function
Adrenal gland anatomy was first described in 1563 by Bartholomeo Eustachius, but
it was not until 1849 that Thomas Addison presented a paper providing evidence of
a physiological role (Addison 1849; Eustachius 1574). In 1937, cortisone was
identified, and eventually synthesised in 1949.
The adrenal glands are paired pyramidal shaped structures lying above or
posteromedial to and occasionally attached to the upper pole of the kidney. Each
gland weighs approximately four grams, regardless of age, body weight, or sex. The
adrenal glands consist of two functionally distinct units; the adrenal cortex and the
adrenal medulla. The adrenal medulla is concerned with the release of epinephrine
and norepinephrine and will not be discussed further. The adrenal cortex is that part
of the gland responsible for glucocorticoid, mineralocorticoid and androgen
production.
2.2.1 Normal Adrenal Physiology
The primary role of the adrenal cortex is the synthesis and release of steroid
hormones into the general circulation. The glucocorticoids have numerous effects,
exerting their effects throughout the body. Indeed, life cannot exist without their
presence in the body.
Glucocorticoids enter the target cells by simple diffusion, and then bind to a specific
glucocorticoid receptor which travel from cytoplasm to nucleus, through which their
effects are transmitted (Okret et al 1984).
The hormone-receptor complex then binds to deoxyribonucleic acid (DNA), thus
regulating gene expression, resulting in either transcriptional activation or inhibition
(Rousseau et al 1973). The complex interacts with specific DNA sequences (known
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as glucocorticoid receptor elements) (Beato 1989). In this way, glucocorticoids exert
their effects on numerous systems in the body.
One of the main effects of glucocorticoids is on carbohydrate metabolism. They
enhance glycogen metabolism by activating glycogen synthase (Hornbrook et al
1966) and inhibiting glycogen phosphorylase (Stalmans & Laloux 1979).
Glucocorticoids also have a major effect on glucose metabolism by activating
glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, increasing
hepatic gluconeogenesis (Exton 1979). Peripheral glucose utilisation is inhibited by
glucocorticoids, in part by directly inhibiting glucose transport into cells (Livingston &
Lockwood 1975).
Glucocorticoids also activate lipolysis in fat tissues. In chronic glucocorticoid excess,
there is a redistribution of body fat, with marked central fat deposition. This lipogenic
effect may be due to hyperinsulinaemia resulting from excess glucocorticoids.
Glucocorticoids have an effect on the immune system and can affect inflammatory
processes. In supraphysiological doses, glucocorticoids suppress immune
responses (Graham & Tucker 1984). However, anti-inflammatory effects are only
seen when pharmacological amounts are given (Fauci 1979).
Other effects of glucocorticoids include their influence on muscle and bone
metabolism and their effects on mineralocorticoid activity, mood and behaviour, and
linear growth and cell development.
2.2.2 Control of Androgen Release by the Adrenal Cortex
The adrenal cortex secretes androgenic steroids, principally
dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulphate (DHEAS) and
androstenedione (Longcope 1986). These are converted peripherally to
testosterone and dihydrotestosterone.
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Control of adrenal androgen release remains unclear. Several factors have been
implicated. ACTH probably plays an important role since androgen concentrations
appear to follow Cortisol concentrations, exhibiting the same circadian pattern of
secretion (Rosenfeld et al 1975).
Other factors may also be involved, such as an additional pituitary factor. Evidence
for this is given by Albertson et al who found that giving ACTH replacement in
hypophysectomised chimpanzees did not normalise androgen secretion (Albertson
et al 1984). Cunningham et al in 1994 also found that there was dissociation of
adrenal androgen and Cortisol secretion in Cushing's syndrome (Cunningham &
McKenna 1994). Isolates from pituitary extracts have been proposed as possible
factors, but this remains controversial.
Other hormones such as prolactin and Insulin-like growth factor 1 (IGF-1) have also
been suggested to have adrenal androgen stimulatory roles, but this seems to occur
only in pathological states (Higuchi et al 1984).
2.2.3 The Adrenocortical Stress Response
Almost any form of stress, either physical or psychological, results in the release of
ACTH followed by an adrenocortical response to this within minutes. The nature of
the stress can be anything from acute anxiety to major trauma. The role of this
Cortisol surge following stress is still not fully understood, but it is known that the
release of Cortisol rapidly mobilises amino acids and fats, making these available as
an energy source and also for the synthesis of glucose for energy utilisation.
2.2.4 Steroid Biosynthesis in the Adrenal Gland
Adrenal steroid hormones are derived from cholesterol, which is converted to
pregnenolone by removal of the C-20 side chain by P-450scc. In the Cortisol
biosynthetic pathway, pregnenolone is then converted to progesterone by
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dehydrogenation of the 3-hydroxyl group and isomerisation of the double bond at C-
5. This is achieved with the enzyme 3p-hydroxysteroid dehydrogenase.
Cytochrome P-450ci7 converts progesterone to 17-OHP by hydroxylation of C-17
and also causes cleavage of the residual two-carbon side chain at C-17 on
pregnenolone. This allows 17-hydroxylated substrates with their side chain intact to
be synthesised as glucocorticoids, and the C19-steroids are directed towards
androgen and oestrogen synthesis. Cortisol synthesis is then completed by
conversion of 17-progesterone to 11-deoxycortisol by 21-hydroxylation by
cytochrome P-450C2i enzyme, and finally conversion to Cortisol by P-450Cn.
Adrenal androgens are synthesised from C-17 steroids. Dehydroepiandrosterone is
formed from 17-hydroxypregnenolone by the action of P-450C17. Androstenedione is
formed by side-chain cleavage of 17-hydroxyprogesterone by P-450C17-
Mineralocorticoids are synthesised from progesterone by hydroxylation at C-21 by
P-450C2i to form deoxycorticosterone. This is then converted to corticosterone by
hydroxylation at C-11, and finally to aldosterone by methyl oxidation at C-18. These
two final steps are catalysed by cytochrome P-450Cn.























































Figure 2.1 Steroid biosynthetic pathway
2.3 Adrenocortical Insufficiency
Adrenocortical deficiency states can originate either from diseases of the adrenal
gland itself (primary adrenal insufficiency), or from disorders of the hypothalamo-
pituitary region (secondary and tertiary adrenocortical insufficiency). (See Table




Autoimmune adrenalitis Post-glucocorticoid therapy
Adrenalectomy Hypophysectomy
Amyloidosis Pituitary aplasia





Haemorrhage Post cranial irradiation
Neoplastic infiltration Sarcoidosis
Xanthomatosis Starvation




Table 2.1. Causes of adrenocortical insufficiency
2.3.1 Primary Adrenocortical Insufficiency
In primary adrenocortical failure (resulting from primary adrenocortical damage), a
lack of Cortisol feedback results in elevated levels of ACTH; a phenomenon used to
advantage in diagnosis. Mineralocorticoid secretion is also affected, resulting in salt
wasting, with hyponatraemia and raised potassium concentrations as well as
hypoglycaemia. The clinical features of adrenocortical insufficiency are dependant
on the rate of loss of adrenal function. In general, the history of primary
adrenocortical insufficiency is short, and the features are severe and acute, the
patient presenting in adrenal crisis. The patient is acutely unwell, hypotensive and
volume depleted, with characteristic changes in the electrolyte levels.
2.3.2 Secondary Adrenocortical Insufficiency
In contrast to primary adrenocortical insufficiency, the symptoms of secondary or
tertiary adrenocortical insufficiency are usually insidious and non-specific, and may
exist for many years before the patient develops acute adrenal failure. Salt wasting
does not occur. Tertiary adrenocortical insufficiency results from hypothalamic
damage, whereas SAI can result from any process affecting the pituitary gland and
affecting ACTH secretion (Table 2.1). In practice, it is difficult to differentiate
between secondary and tertiary insufficiency.
2.3.3 Diagnosis of Adrenocortical Insufficiency
The features of Addison's disease tend to be obvious at presentation, with the
characteristic features of hyperpigmentation and reverse pigmentation, biochemical
derangement (hyponatraemia and hyperkalaemia), a poor Cortisol response to
synacthen, and raised circulating concentrations of both ACTH and plasma renin.
By contrast, the symptoms of SAI, which include tiredness, lethargy, malaise, and
increased frequency of trivial upper respiratory infections of prolonged duration, are
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insidious and very similar to those which can occur after cranial irradiation and
radiotherapy.
A specific biochemical test does not exist for SAI (see below) and diagnosis is
difficult, unless the patient has florid symptoms.
2.4 Adrenal function tests in hypoadrenalism
In order to determine the integrity of the HPA axis with reference to diagnosing
Cortisol deficiency states, steroid hormones are either measured at various times of
the day, or provocation tests are performed which stress the axis and give an
estimate of the HPA reserve. In general, little further information can be gained in
diagnosing secondary hypoadrenalism by measuring ACTH. At the time of writing,
there are no assays available to sensitively determine CRH concentrations.
However, the usefulness of measuring circulating CRH is questionable, as
concentrations in peripheral blood are low.
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Physiological tests Provocation tests
random plasma/salivary
cortisol/adrenal steroids
Cortisol response during insulin
hypoglycaemia
diurnal variation in plasma/salivary
Cortisol




adrenal steroid response to
metyrapone
urinary steroid profiles Cortisol and ACTH responses to
Corticotrophin releasing hormone
Table 2.2. Summary of tests used for detecting adrenocortical
Insufficiency
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2.4.1 Physiological tests used to assess Adrenocortical
Function
These tests assess the HPA axis by measuring steroid hormones produced from the
adrenal cortex without subjecting the patient to any stimulus that may influence
steroid production. In practice this is very difficult to perform, as even simple
stresses (such as the thought of venepuncture) have been shown to affect steroid
secretion.
Several attempts have been made to establish the usefulness of physiological tests
in assessing adrenal function (Allin et al 1984; Hagg et al 1987).
Early morning serum Cortisol concentrations, taken between 7a.m and 9a.m may be
helpful in diagnosing adrenocortical insufficiency (Hagg, Asplund, & Lithner 1987).
However, this method can be unreliable, as in many cases, the actual time of peak
for each individual may be missed.
The use of venepuncture to assess adrenal function can also provide erroneous
results, particularly in children, as the stress of the procedure, or even the
anticipation may affect adrenal Cortisol release.
Urinary steroid profiles and urinary free Cortisol determinations have been
advocated as useful non-invasive methods of assessing adrenal function in children,
provided that the technique of urine collection is meticulous (Gomez et al 1991;
Honour et al 1991). However, in younger children this may not be possible, as
collection of urine is difficult to perform accurately.
2.4.2 Provocation tests used in the diagnosis of
Adrenocortical Insufficiency
Provocation tests assess maximal steroid release to a specific stimulus, such as
hypoglycaemia, metyrapone inhibition, or ACTH stimulation. The tests are
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essentially non-physiological and assess adrenal reserve rather than actual
function.
Since its introduction (Jacobs & Nabarro 1969), the insulin induced hypoglycaemia
test (ITT) has been looked upon as the "gold standard" in many studies evaluating
HPA function. However, there have been reports of patients who clinically were felt
to be Cortisol deficient, but who had a normal Cortisol response to hypoglycaemia
and an abnormal response to synacthen (Borst et al 1982). Perhaps more
importantly, the ITT is not without risk, particularly in patients with adrenocortical
insufficiency.
The ACTH stimulation test is frequently used to assess adrenocortical function
(Lashansky et al 1991; Lindholm & Kehlet 1987). The standard Cortisol response to
a pharmacological dose (250|ag) of synthetic ACTH analogue as Synacthen, 1-24
ACTH (Ciba-Geigy) is determined. The ACTH dose is several hundred times greater
than the concentrations reached under physiological conditions. The rationale for
using ACTH stimulation in the assessment of SAI is that an already under stimulated
adrenal gland will show a sluggish response to exogenous ACTH. In general, the
Cortisol response to ITT and Synacthen are broadly comparable (Jackson et al
1994). However, discrepancies have been noted, making interpretation difficult in
individual patients. Moreover, some patients with SAI have been shown to have a
normal response to pharmacological doses of ACTH analogue (Cunningham,
Moore, & McKenna 1983).
Alternatively, the Cortisol response to infusions of supposedly physiological amounts
of ACTH may be assessed (Landon et al 1964; Landon 1967). More recently, in
1991, Crowley et al used a low dose ACTH test to assess adrenocortical function
(Crowley et al 1991; Dickstein et al 1991). Low doses of intravenous Synacthen
(500ng/1.73m2 body surface area) were shown to produce similar results when
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compared with the standard 250pg ACTH test in normal subjects. Using a lower,
more physiological dose may provide more accurate information of adrenal function.
The metyrapone test has been used to specifically assess adrenocortical reserve
and diagnose ACTH deficiency (Best et al 1980; Dickstein et al 1986; Gans &
Ulstrom 1962; Limal et al 1976; Strott et al 1969). Metyrapone is a specific 11(3-
hydroxylase inhibitor (See Figure 2.1). Administration of metyrapone results in a fall
in plasma Cortisol concentration that increases hypothalamo-pituitary drive, causing
increased production of steroid hormones proximal to the block. These can be
measured in plasma (11-deoxycorticosterone and 11-deoxycortsol) and, more
conveniently in children, in urine (Ochs & Mulhern 1988). Metyrapone is not without
potentially serious side effects, as it effectively renders patients hypoadrenal. The
original metyrapone test, described in 1959, was very unpleasant, and potentially
dangerous. However, a single oral dose test has been used in children producing
minimal adverse effects (Jubiz et al 1970).
Finally, the HPA axis may be assessed using the Cortisol response to CRH (Dahl et
al 1992; Ross et al 1986). The effectiveness of this method is currently under
evaluation, but apart from its usefulness in differentiating hypothalamic from pituitary
lesions, it is likely to have similar problems as the ACTH test.
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2.5 Radioimmunoassay of Steroid Hormones
Radioimmunoassay (RIA) was first described in 1960 following the development of
techniques that rendered the handling of radioisotopes relatively safe (Berson &
Yalow 1956). Isotope usage enabled the detection of very small quantities of
substances. Since hormones are present in the body in very small amounts, this
development revolutionised endocrinology. The use of antibody as a binder was
developed in 1960 by Yalow and Berson when RIA for insulin was developed (Yalow
& Berson 1960). Subsequently, Ekins developed a competitive protein-binding
assay for thyroxine (Ekins 1960). These two immunoassays formed the basis of
further immunoassay development.
The basic concept of RIA is one of competitive binding of antibody to antigen or
ligand. The antibody binds to antigen in a reversible reaction. If more than one type
of ligand is present, there is competitive binding between the two ligands and the
antibody binding sites. The distribution of antigen between the bound and free
phase depends on the total amount of antigen present. In this way, the total amount
of antigen present can be calculated.
The principles of RIA are basically the same in all assays. A standard curve is
constructed by incubating fixed amounts of antibody and labelled antigen with
varying concentrations of unlabelled ligand. From this, a curve is plotted of
percentage of antibody bound against concentration of unlabelled ligand. If plotted
on a log scale, a sigmoid curve is obtained.
The accepted requirements for a RIA are the use of a purified antigen, a purified
tracer ligand, specific antibody, and a robust method for distinguishing between or
separating bound and free ligand.
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It is essential that a highly purified ligand is used in order to measure the antibody
bound and free fractions. Radio-iodine isotope (125l), is highly specific, is easier to
detect and is cheaper to detect than the alternative tritium. Expensive scintillation
fluid is not needed with iodine label. Instead multihead counters are used which
allow for rapid sampling.
Improving sensitivity of an assay may be achieved by altering the concentration of
antibody, the total volume of antibody and ligand, and the environment in which the
assay is performed (i.e. the temperature). The specificity of an assay can be
improved by changing the characteristics of the antibody such as improving binding
characteristics and reducing cross-reactivity.
2.6 The Use of Salivary and Capillary Steroids
2.6.1 Salivary Steroids
Saliva as a medium is attracting interest as an investigative and screening tool. It is
increasingly being used to monitor antibody levels to both viruses and antibodies,
concentrations of drugs (e.g. phenytoin), and to measure steroid hormones such as
Cortisol, 17-OHP, androstenedione, testosterone, and DHEA (Malamud D. 1992).
The first assays of steroids in saliva were performed in 1959, when Shannon et al
performed pioneering work in measuring 17-hydroxycorticosteroids in the parotid
fluid of healthy adult males using a calorimetric method (Shannon et al 1959). It was
shown then that there was a diurnal variation of the 17-hydroxycorticosteroids, and
also that there was a response of salivary steroids to corticotrophin. However, large
volumes of saliva were required (over 10 ml) because of assay insensitivity, and a
collecting device was necessary; possibly because of this, the challenge to use
saliva in endocrinology was not accepted!
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With the advent of RIA, hormone assays have become much more sensitive,
resulting in smaller sample requirements (less than 200 pi). Much of this later work
on the use of saliva was performed at the Tenovus Institute for Cancer Research in
Cardiff (Riad-Fahmy et al 1982). Several other workers have now developed
salivary steroid assays for use in particular aspects of clinical and psychological
medicine (Al-Ansari et al 1982; Bailey & Heitkemper 1991; Dabbs et al 1991;
Hiramatsu 1981; Kirschbaum & Hellhammer 1989), or have adapted serum assays
for use in saliva (Al-Ansari, Perry, Smith, & Landon 1982).
The use of saliva has advantages over serum or plasma and even urine (see Table
2.3). Collecting saliva is relatively simple and stress free. Initial collecting devices
were unsatisfactory due to the steroids adhering to the porous material used
(Walker et al 1990). However, use of these collecting devices ("salivettes") can be
helpful in situations requiring long-term storage of samples at room temperature
(Chen et al 1992). The simplest method of collection has been either by aspirating
saliva from the oral cavity following citric acid stimulation, or by simply spitting
directly into clear sterile containers.
Saliva collection does not require medical or nursing staff supervision, allowing it to
be performed in the stress-free environment of the patients' own home. This is
particularly attractive in the paediatric population, since it avoids the problems
associated with venepuncture, and its attendant ethical and practical constraints,
such as multiple sampling over long periods.
Uncertainty still exists regarding the validity of the methods employed in assaying
hormones in saliva. There does still seem to be an emotive bias against the use of
saliva possibly due to the clinicians' perception that a blood sample is somehow
"better". Saliva is often compared with sputum, which also tends to avert clinicians
from collecting it.
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Free plasma hormone concentrations are thought to reflect the biologically active
fraction of the hormone but are difficult to measure; the procedures involve
ultrafiltration or equilibrium dialysis, both of which are technically demanding and
time consuming. Measurement of hormones in saliva relates to the free, unbound
circulating level of the hormone rather than total levels. Poteczin et al have
demonstrated excellent correlation between plasma free progesterone and salivary
progesterone concentrations during pregnancy and Smith et al have shown a close
relationship between free testosterone measured in plasma and testosterone in
saliva (Smith et al 1979). Salivary Cortisol concentrations have been shown to be
directly proportional to serum free Cortisol concentrations (Reid et al 1992; Riad-
Fahmy, Read, Walker, & Griffiths 1982; Tunn et al 1992; Umeda et al 1981; Vining
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One argument against the use of saliva is the claim that salivary hormone
concentrations are inversely related to salivary flow rate. There is now good
experimental evidence that this is not the case (Riad-Fahmy, Read, Walker, &
Griffiths 1982).
A recognised problem is falsely high salivary steroid concentrations due to blood
contamination. Care is required during saliva collection, samples should not be
collected after tooth-brushing, which may damage the buccal mucosa and gum
margin, resulting in blood contamination (Schramm etal 1993).
There have to date been many assays either developed or adapted for measuring
Cortisol in saliva (Hiramatsu 1981). These assays are simple, sensitive, and specific.
To date, however, the majority of these assays have been developed using 'in-
house' reagents for research purposes (Landon et al 1982), although some
commercial serum assays have been adapted for use with saliva (Al-Ansari, Perry,
Smith, & Landon 1982).
2.6.1.1 Application of Salivary Steroid Assays
Salivary Cortisol concentrations have been shown to follow the same diurnal pattern
as do serum concentrations (Bailey & Heitkemper 1991; Walker et al 1982). Salivary
Cortisol has also been shown to rise in response to Synacthen and insulin induced
hypoglycaemia with a similar incremental rise compared with serum values (Laudat
et al 1988).
Salivary Cortisol concentration correlates extremely well with plasma free Cortisol
concentration, suggesting that they are as valuable as plasma concentrations (Reid,
Intrieri, Susman, & Beard 1992; Tunn, Mollmann, Barth, Derendorf, & Krieg 1992;
Umeda, Hiramatsu, Iwaoka, Shimada, Miura, & Sato 1981; Vining et al 1983b;
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Vining & Mcginley 1982; Walker, Riad-Fahmy, & Read 1976; Woodside, Winter, &
Fisman 1991).
Moreover, salivary Cortisol correlate extremely well with serum total Cortisol and free
Cortisol (Riad-Fahmy, Read, Walker, & Griffiths 1982; Tunn, Mollmann, Barth,
Derendorf, & Krieg 1992). Therefore, salivary Cortisol concentrations accurately
reflect serum free and total Cortisol concentrations.
Measurement of salivary Cortisol in response to ACTH provides a useful assessment
of adrenal reserve (Peters et al 1982b). In fact, the percentage rise of Cortisol in
saliva is greater than in serum (Riad-Fahmy, Read, Walker, & Griffiths 1982).
One important concern with regard to salivary Cortisol is the conversion of Cortisol to
cortisone in the submaxillary gland in the mouth due to the presence of 11 (3-
hydroxysteroid dehydrogenase. This may in theory affect the relationship between
plasma free and salivary Cortisol. Studies performed suggest that there is excellent
correlation between plasma free and salivary Cortisol (Brooks & Brooks 1982;
Peters, Walker, Riad-Fahmy, & Hall 1982b; Peters etal 1982a; Umeda, Hiramatsu,
Iwaoka, Shimada, Miura, & Sato 1981). These studies imply that the correlation
holds true despite cortisol/cortisone interconversion in saliva.
When studying different age groups and sexes, it has been shown that the
reference ranges for early morning samples in males, females and children are not
significantly different. Moreover, the range of values in different studies in which
different assay techniques were used, were generally in good agreement.
Sex hormone binding globulin (SHBG) has been detected in very small amounts in
saliva. However, the effect on Cortisol levels in saliva is minimal (Selby et al 1988).
SHBG levels may also be higher in blood contamination; this may be another factor
resulting in falsely high salivary Cortisol levels.
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Steroids such as 17-OHP and androstenedione (Turkes & Read 1982) have also
been measured in saliva, but unfortunately there is little normative data available for
these steroids (Turkes & Read 1982; Young et al 1988b). Some work has been
done on the use of salivary 17-OHP in monitoring children with congenital adrenal
hyperplasia (CAH) (Young et al 1988a).
Other steroid hormones such as progesterone and oestrogens have also been
measured in saliva. These have been used in monitoring fertility, and are a useful
adjunct to fertility control.
2.6.2 Capillary Steroids
The use of capillary blood spot samples is becoming more widely used as a method
of patient monitoring. The use of home blood glucose monitoring in diabetic patients
is a major part of diabetic monitoring and blood glucose control.
Blood spot 17-OHP profiles have been used for some time to monitor the control of
patients with congenital adrenal hyperplasia (Young, Robinson, Read, Riad-Fahmy,
& Hughes 1988a). The use of androstenedione in monitoring CAH has also been
reported, and the use of androstenedione profiles in conjunction with 17-OHP has
been advocated as a more accurate method of assessing management of these
patients (Hughes & Winter 1978).
Measurement of blood spot Cortisol in the screening of children at risk of developing
SAI therefore seems attractive, in a similar way to saliva. However, blood spot
sampling is more invasive than saliva collection. There have been no reports on the
use of blood spot Cortisol estimations to date.
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2.7 Adrenal Function in Childhood Cancer Survivors
There have been surprisingly few reports of HPA dysfunction in childhood cancer
survivors. In leukaemia survivors who have not suffered relapse, there are, as far as
we are aware, no reports of SAI. There is no evidence of significant disruption of
spontaneous ACTH or Cortisol secretion in children who had received low dose
cranial irradiation (18-24 Gy) (Crowne et al 1993; Wallace et al 1990) when
compared with normal children (Wallace et al 1991).
In BMT survivors, the incidence of HPA dysfunction was reported to be 24%
(Sanders, Pritchard, Mahoney, Amos, Buckner, Witherspoon, Deeg, Doney,
Sullivan, Appelbaum, Storb, & Thomas 1986). However, this was based on the
metyrapone test, measuring 11-deoxycortisol levels post-metyrapone. None of the
patients in this study were symptomatic.
In brain tumour survivors, the expected incidence of HPA dysfunction should be
significantly higher. However, once again there are few reports on HPA
abnormalities. In 1989, a report suggested a prevalence of one third of adult
patients with multiple endocrine deficits having ACTH deficiency (Littley, Shalet,
Beardwell, Ahmed, Applegate, & Sutton 1989). In childhood brain tumour survivors,
there are reports in which children are reported to require steroid replacement
therapy, with a presumed diagnosis of HPA dysfunction (Brown, Lee, Eden,
Bullimore, & Savage 1983).
The prevalence of ACTH deficiency in adult cancer survivors is said to be similar to
that of gonadotrophin deficiency (Littley, Shalet, Beardwell, Ahmed, Applegate, &
Sutton 1989). However, this does not seem to be the case in children (personal
observation), although this has not been conclusively shown. Recognising ACTH
deficiency is difficult as the clinical features tend to be non-specific, and very similar
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to the symptoms experienced post-radiotherapy. This can lead to a delay in
diagnosis. Moreover, the diagnosis of ACTH deficiency may not always be possible
using conventional dynamic tests (Tsatsoulis et al 1988).
In 1968 a group looked specifically at pituitary-adrenal function in patients with
untreated pituitary tumours and found that the response to various stimuli
(metyrapone, corticotrophin, pyrogen, insulin and surgical stress) varied (Jenkins &
Else 1968). However, all had an adequate response to surgical stress. They
concluded that the responses may not give an accurate indication of impairment of
hypothalamo-pituitary-adrenal axis, and may not indicate whether the patient will
have an appropriate physiological stress response.
2.7.1 Problems in Clinical and Laboratory Diagnosis
The main problems in diagnosis of SAI in cancer survivors are the lack of clinical
pointers to diagnosis, coupled with interpretative difficulties of the commonly used
diagnostic tests. This makes definitive diagnosis difficult and leads to either
unacceptable false positive or false negative diagnosis of SAI, hence the need for
the study.
2.7.2 Design of Study
The aim of the study was to develop a screening technique for detection of
hypoadrenalism in children at risk of developing SAI. The study consisted of three
phases:
1. The development of a relatively non-invasive test for assessing adrenocortical
function using saliva and/or capillary blood samples.
For this, a sensitive radioimmunoassay for measuring Cortisol was developed.
Assays for salivary 17-OHP and androstenedione were adapted from existing
capillary blood spot samples.
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The measurement of these three steroid hormones may be able to provide more
sensitive indicators of developing SAI.
2. To obtain normative data for these three steroid estimations in both saliva and
capillary blood spots from 24 hour profiles in children.
3. To assess adrenocortical function in childhood cancer survivors, using currently
available diagnostic techniques, as well as using saliva and capillary blood spot
profiles.
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3 Subjects, Materials and Methods
3.1 Control Population
3.1.1 Recruitment of Control Subjects
Ethical approval was granted to approach schools within the area surrounding the
Royal Hospital for Sick Children (RHSC), Glasgow, for volunteers to provide
samples of saliva. Permission was then given by the Regional Education Authority
to contact schools in this area. Ethical approval was, however, not granted to obtain
capillary blood spot samples from healthy volunteers including the siblings of
childhood cancer survivors. The Yorkhill ethical committee felt that finger prick
sampling on healthy children was too invasive and not in the best interests of the
volunteers.
Nine schools were approached, and of these, four schools agreed to allow their
children to take part in the study.
3.1.2 Field Work
Four schools agreed to take part; three were primary schools and one a secondary
school. The secondary school and one of the primary schools served an area close
to the University of Glasgow, and for this reason there was a range of different
ethnic groups in those schools, predominantly Middle Eastern and Asian, as well as
Caucasian.
Children were excluded from the study if they were known to be unwell, were
suffering from a chronic illness, or were on any long-term treatment (e.g. steroid
inhalers).
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An information sheet and consent form was given to each child in the primary
schools and to all children up to the age of 15 years in the secondary school
(appendix 1a, b, c, d; 2). In two of the primary schools the head teachers felt that the
parents should be offered the opportunity to discuss the project with the author for
further information. Consequently, evening meetings were arranged where the
interested parents could obtain further information and had the opportunity of asking
further questions regarding the study. In total, 340 children gave written consent to
participate in the study. Following this, each school was visited by the author and
Miss Wendy F. Paterson (WFP, Auxologist in the Department of Child Health,
RHSC, Yorkhill, Glasgow). The children were measured by WFP and given
collecting bottles and instruction sheets regarding saliva collection and storage.
The children were also asked to provide samples of saliva if they were unwell (e.g.
pyrexial with a temperature greater than 39°C, and unable to attend school) at any
time over a 2 month period.
3.1.3 Auxology of the Control Population
The control subjects were measured using a portable free-standing stadiometer. All
children were stretched in order to reduce the measurement changes due to
posture. The children were weighed using portable electronic weighing scales and a
portable stadiometer. Height and weight was measured by a single observer (WFP).
Pubertal staging was not performed.
3.1.4 Collection of Salivary Samples from the Control
Population
Saliva samples were collected at home in control subjects. The children were asked
to rinse their mouth with clear water for approximately 30 seconds, and then to
empty their mouths. They were then asked to spit directly into clear plastic tubes
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after waiting for one minute. Once they had collected between one and two millilitres
of saliva, they were asked to freeze the sample.
The subjects were asked to avoid collecting samples for at least one hour after they
had brushed their teeth, and after eating or drinking (Appendix 2). Up to six samples
of saliva were collected over 24 hours, at the following times: 8 a.m.; 11 a.m.; 5
p.m.; 8 p.m.; 11 p.m. (if the subjects are still awake), and 8 a.m. the following day.
3.2 Patient Population
3.2.1 The West of Scotland Experience
The haematology and oncology unit at the RHSC, Glasgow is a tertiary referral
centre, providing services to the West of Scotland, for all childhood malignancies.
(Fig. 3.1) The regional bone marrow transplant unit for Scotland is also located in
RHSC Glasgow and the oncology centres in Edinburgh and Aberdeen currently refer
all their patients to Glasgow for bone marrow transplantation.
3.2.1.1 Leukaemias
Since 1975, 462 children (275 boys, 187 girls) have been treated in Glasgow with
leukaemia of various types (Fig. 3.2, 3.3). There has been a steady increase in the
number of patients treated since 1975. The commonest haematological malignancy
treated in Glasgow is ALL, accounting for nearly 80% of haematological
malignancies treated. The survival rate for childhood leukaemias for children treated
in Glasgow has continued to improve and is currently 72% in females, and 65% in
males treated between 1985 and 1989 (greater than 10 year survival). The overall
survival rate for all children treated between 1975 and 1994 is 25% in males and
28% in females (Fig. 3.4, 3.5, 3.6, 3.7). The charts show a steady improvement in
survival over time, presumably due to improved therapeutic techniques.
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Figure 3.2. Diagnostic Breakdwn ofchildren treated for
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Figure 3.6. Survival curves for haematological malignancies in
females treated in RHSC, Glasgow; 1975 to 1989
3.2.1.2 Bone Marrow Transplantation
Bone marrow transplantation as a treatment for childhood leukaemias and certain
tumours (e.g. neuroblastomas) was first performed in Glasgow in 1975. Since then,
bone marrow transplantation has been performed in 88 children (35 girls, 53 boys).
Most transplants have been performed for treatment of relapse of leukaemia
(commonly acute lymphoblastic leukaemia) (Fig. 3.7). Other indications include high
risk leukaemia (AML, T-cell ALL) in first remission, aplastic anaemia, and selected
solid tumours (e.g. neuroblastoma).
The regimen for bone marrow transplantation in malignant disease in Glasgow
consists of conditioning with cyclophosphamide and total body irradiation (TBI),
giving 1440 cGy in 8 fractions.
The overall 10 year survival rate at RHSC, Glasgow for these children is 57% (Fig.
3.8). However, for the different diagnostic groups treated with BMT, the mortality
rate is variable, with the best survival rate for boys with ALL (Fig. 3.9).
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3.2.1.3 Brain Tumours
RHSC Glasgow is a tertiary referral centre for the management of childhood brain
tumours of various types (Fig. 3.10; 3.11). Surgical treatment takes place in the
nearby Institute of Neurosciences, with subsequent management under the care of
the paediatric oncologists and radiotherapists. The commonest brain tumours
treated are medulloblastoma and astrocytoma, accounting for 124 out of 212 (58%)
children treated. Overall, 105 boys and 107 girls have been treated between 1975
and 1995. The overall survival rate is comparable with national figures; the five year
survival rate is approximately 60%. The cumulative survival rates are also
comparable with improvements in survival for brain tumours overall (Fig. 3.12, 3.13).
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Figure 3.10. Diagnostic breakdown ofchildren treated for
brain tumours in Glasgow, 1975 to 1995.
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Figure 3.11. Number of children treated for brain tumours in RHSC,
Glasgow (1975 to 1995).
 
3.2.2 Criteria for Patient Selection
Patients included in the study were those who were at least one year post
completion of their anti-cancer treatment and who had received a sufficiently high
dose of cranial irradiation to put them at risk of developing SAL Patients included
were those who at the time were willing to take part in the study. This meant that
inclusion into the study was relatively arbitrary.
These included:
• Patients with ALL receiving cranial irradiation who then had acute relapse
requiring further chemotherapy and/or cranial irradiation.
• Patients with brain tumours who had received high dose cranial irradiation (equal
to or greater than 3000cGy) as part of their treatment.
• Patients who had received a bone marrow transplant either as the treatment of
their initial disease, (e.g. acute myeloid leukaemia, stage four neuroblastoma), or
who had received a bone marrow transplant for relapse of their initial disease
(e.g. ALL).
• Patients already on steroid replacement for suspected hypoadrenalism were
included in the study if the diagnosis of SAI was considered on review to be
inconclusive.
3.2.3 Exclusion Criteria
Patients who were not included in the study were those with ALL in first remission
who had received standard ALL treatment - two years chemotherapy and cranial
irradiation, 1800cGy. Also excluded were children with other leukaemias treated with
chemotherapy only, children with solid tumours out with the hypothalamo-pituitary
axis which were not treated with radiotherapy, and children in whom the diagnosis of
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SAI was considered so likely that discontinuation of their steroid therapy might be
hazardous.
Patients were also excluded from the study if patients or their parents requested not
to be entered.
3.2.4 Auxology
The study patients' growth and development were monitored regularly in the out¬
patient clinics at the Royal Hospital for Sick Children, Glasgow. The patients' height
was measured by trained auxiliary staff using fixed wall-mounted stadiometers,
which were regularly calibrated.
Patients were weighed using electronic sitting scales.
3.2.5 Collection of salivary and capillary samples in study
patients
3.2.5.1 Salivary samples
Saliva samples were collected at home in the same way as in the control subjects.
The children were asked to collect samples when they were well and when they
were unwell.
3.2.5.2 Capillary samples
Capillary blood spot samples were collected from the study patients but not the
controls. Capillary blood was taken from the finger immediately after collecting saliva
samples, using an Autolet lite capillary blood sampling device. Blood was collected
onto filter paper strips and left to dry at room temperature.
3.2.6 Low-dose Synacthen Test
A low dose Synacthen test was performed in study patients who had either not had
anterior pituitary function tests, or in those who had had an insulin tolerance test
more than one year previously.
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Patients who had had an ITT performed more recently than this, also had a low
dose Synacthen test if it was felt they had features, which were suggestive of SAI.
A low dose synacthen test was performed according to a previously published
protocol (Crowley, Hindmarsh, Holownia, Honour, & Brook 1991). Synacthen
(500ng/1,73m2 body surface area) was administered intravenously and the
response assessed by measuring plasma Cortisol concentrations from plasma
samples taken at intervals over 35 minutes (See appendix 4 for detailed protocol).
3.2.7 Insulin Tolerance Test
An insulin tolerance test (ITT) was performed as part of the routine test to assess
anterior pituitary function. These tests are performed routinely in RHSC at least one
year following completion of anti-cancer treatment in those children at risk of
developing endocrine deficit. The ITT was performed by giving short acting insulin in
a dose of 0.1 or 0.15 units/kg intravenously, and measuring blood glucose, growth
hormone and Cortisol over the following 2 hours. A TRH test and LHRH test was
performed at the same time (see appendix for detailed protocol).
3.2.8 Single Dose Oral 3 Day Urinary Metyrapone Test
A urinary metyrapone test was performed in five patients by giving metyrapone in a
dose of 500 mg/m2 body surface area, collecting urine for 24 hours before
administration, and then for three 24 hour periods thereafter. Urinary steroid profiles
were performed using capillary column gas chromatography/mass spectrometry
(See Appendix 7 for protocol).
84
4 Materials and Methods used in Assay
Development
4.1 Apparatus
The apparatus listed below were used in the assay development:
• A NE-1600 Gamma Counter (Nuclear Enterprises, Edinburgh, Scotland) was
used to measure gamma radiation.
• Centrifugation was carried out using a M.S.E. Coolspin 2 centrifuge (Medical
Scientific Equipment, Manor Road, Crawley, West Sussex, England).
• Borosilicate glass disposable culture tubes were used; size 12x75 mm and
16x100 mm.
• Plastic tubes (5 ml and 2.5 ml size) were used for storing samples and standards
at -20°C. Disposable sarstedt pipette tips were used throughout. These were
obtained from Sarstedt Ltd., Beaumont Leys, Leicester, England.
• Oxford sampler pipettes (50 pi, 100 pi, 200 pi, 500 pi, 1 ml) were used throughout
for pipetting samples and standards.
• Repeat pipetting was performed using a BCL repeating pipette (Boehringer
Corporation Limited, Bell Lane, Lewes, East Sussex, England).
• An SMI Digitron electronic pipette (Sherwood Medical Industries Limited, County
Oak Way, Crawley, East Sussex, England) was used to pipette small samples of
label for dilution.
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• For solvent extraction, an S.M.I. Multi-tube Vortexer from Alpha Laboratories,
Easteigh, Hampshire, England, and a Buchler Vortex evaporator from Arnold
Horwell, London, England, were used.
• Filter paper for blood spot strips (code 31 ETCHR; catalogue number 3031.915)
was obtained from Whatman International Ltd., Maidstone Kent, England.
• A Watson-Marlow pump was used for suctioning the supernatant following
washing and centrifuging test tubes (obtained from Falmouth, Cornwall,
England).
• Data analysis was performed on an Apple computer using the WHO program for
Radioimmunoassays, by P.R. Edwards (Department of Nuclear Medicine,
Middlesex Hospital, London, England).
• For measuring control children, a free standing stadiometer was used (Raven
Equipment, Castlemead Equipment, 12 Little Mundells, Welwyn Garden City,
Hertfordshire, AL7 1EW).
• For measuring the study group, a fixed wall-mounted Harpenden stadiometer
was used (Holtain, Dyfed, Wales).
• Soehnle electronic weighing scales were used for weighing the control group
(CMS weighing Equipment Limited, 18 Camden High Street, London, NW1 OJH).
4.2 Reagents
• All common reagents and solvents were of 'AnalaR' grade and were from either
B.D.H. Chemicals Ltd. or Sigma Chemical Co., Dorset, England.
• Steroids were obtained from Sigma Chemical Company.
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Hexane and diethyl ether were obtained from Rathburn Chemicals Ltd.,
Walkerston, Scotland.
Newly expired red blood cells were obtained from Blood Transfusion Service,
Glasgow Royal Infirmary, Glasgow, Scotland.
Sheep anti-cortisol antibody was obtained from the sheep antibody production
unit (SAPU), Scottish blood transfusion unit, Law hospital, Scotland.
Sheep anti-cortisol antibody (code number HP/S/631-2C ) was purchased from
Guildhay Antisera, University of Surrey, England.
Sheep anti-cortisol antibody (code number so20 lot M421) was purchased from
Guildhay Antisera, University of Surrey, England.
17-hydroxyprogesterone antibody was raised in-house by A.M. Wallace.
Rabbit antiserum was raised against 17-hydroxyprogesterone-3-
carboxymethyloxime-bovine serum albumin (code W2B). This was
microencapsulated (by A.M. Wallace) before use (Wallace & Wood 1984).
Androstenedione antibody was raised in-house by A.M. Wallace (Thomson et al
1989). Rabbit antiserum was raised against androstenedione-3-
carboxymethyloxime-bovine serum albumin.
Cortisol radio-label (cortisol-3-carboxymethyloxime[125l]-iodohistamine) was
prepared in-house, or purchased from Amersham International pic., Lincoln Hall,
Green End, Aylesbury, Buckinghamshire, England (Code IM129).
17-hydroxyprogesterone radio-label (17-hydroxyprogesterone-3-
carboxymethyloxime[125l]-iodohistamine) was prepared in-house.
Androstenedione radio-label (Androstenedione-3-carboxymethyloxime[125l]-
iodohistamine) was prepared in-house.
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• Encapsulated antibody - Permeable Antibody-containing Microcapsules (PAM)
Anti-cortisol antibody encapsulated in semipermeable nylon microcapsules in the
form of a suspension (by A.M. Wallace) before use (Wallace & Wood 1984).
PAM 251 - SAPU Cortisol antibody, code no.
PAM 253 - Cardiff Cortisol antibody, code no. R9B4.
PAM 254 - Guildhay Cortisol antibody (400 pi),
code no. HP/S/631-2C.
PAM 256 - Guildhay Cortisol antibody (100 pi),
code no. HP/S/631-2C.
PAM 257 - Guildhay Cortisol antibody (100 pi),
code no. HP/S/631-2C.
PAM 258 - Guildhay Cortisol antibody (100 pi),
code no. S020 lot M421.
4.2.1 Calculations
Area under the curve was calculated using the equation:
(t2-t1)(y1+y2)+(t3-t2)(y2+y3)+(t4-t3)(y3+y4)+(t5-t4)(y4+y5)+(t6-t5)(y5+y6)
where t corresponds to the time the sample was taken in hours, y corresponds to
the concentration of steroid hormone at the corresponding time (Matthews et al
1990).
The equation was adjusted according to the number of samples taken over 24
hours. If there were less than five samples in 24 hours, then area under the curve
was not calculated.
Statistical calculations were performed using the Minitab program (version 9.0;
Clecom microcomputer specialists, The Research Park, Edgbaston, Birmingham).
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4.2.2 Solutions and Buffers
The following solutions and buffers were used in the salivary and capillary blood
spot assays.
4.2.3 Phosphate Buffer
Phosphate buffer (0.05M, pH 7.4), was used as a basic radioimmunoassay buffer for
the salivary steroid assays. It was made by mixing two solutions together:
Solution A (0.25M sodium dihydrogen orthophosphate solution)
This was prepared by dissolving 78 g NaH2P04.2H20 in distilled water and made up
to two litres.
Solution B (0.5M disodium hydrogen orthophosphate solution)
This was prepared by dissolving either:
142 g Na2HP04 (anhydrous)
358 g Na2HP04.12H20
178 g Na2HP04.2H20
in distilled water and making up to two litres.
Solution A (30 ml) was added to solution B (120 ml) and mixed.
Sodium Chloride (17.5 g) was dissolved in 250 ml of distilled water. This was added
to the above mixture and the solution made up to two litres with distilled water. The
pH was checked and adjusted to pH 7.4 by adding either acid (hydrochloric acid) or
alkali (sodium hydroxide solution) as appropriate.
4.2.4 Salivary Assay Buffer
This was prepared by adding sodium azide (500 mg/L) and gelatine (1 g/L) to the
phosphate buffer.
The solution was stored at 4°C for up to 6 months.
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4.2.5 Citrate/Phosphate Buffer
The citrate/phosphate buffer (pH 4.0), was used in the capillary blood spot Cortisol
assay. It was prepared by mixing two solutions together:
Solution A (0.1 M citric acid)
This was prepared by dissolving 21 g citric acid in one litre of distilled water.
Solution B (0.2M disodium phosphate solution)
This was prepared by dissolving 35.6 g Na2HP04.2H20 in one litre of distilled water.
1 g/L gelatin was then added to each solution.
For a solution of pH 4.0, 62 ml of solution (A) was added to 38 ml of solution (B).
The pH was checked and adjusted to pH 4.0.
The solution was stored at 4°C and kept for up to 6 months.
4.2.6 Isotonic Saline
Isotonic saline (0.9% NaCI w/v) was prepared by dissolving sodium chloride (9g) in
one litre of distilled water.
4.2.7 Wash Solution
Wash solution (0.9% NaCI w/v, 0.1% gelatin w/v) was prepared by adding gelatin
(1g) to each litre of freshly prepared isotonic saline and mixing thoroughly.
A fresh solution was prepared for each assay.
90
4.3 Preparation of Standards
4.3.1 Salivary Cortisol Standard Solutions
0 A stock solution of 500 pmol/l of Cortisol in ethanol was made by dissolving
Cortisol (18 mg) in ethanol (100 ml).
0 The stock solution was diluted 10 times to give an intermediate solution of 50
pmol/L (1.8 mg/ml).
0 An aliquot of 80 jnl of the intermediate solution was placed in a volumetric flask. A
volume of 125 ml of salivary assay diluent was added to give a working solution
of 32 nmol/L (11.6 ng/ml).
0 Working standards were prepared by serial dilution of the working solution (0;
0.13; 0.25; 0.5; 1; 2; 4; 8; 16; 32 nmol/L).
0 Aliquots (200 pi) of each standard solution were pipetted into appropriately
labelled plastic tubes, sealed and stored at -20°C.
4.3.2 Salivary 17-Hydroxyprogesterone Standards
0 A stock solution of 3 pmol/L of 17-OHP (molecular weight 330.5) in ethanol was
made by dissolving 17-Hydroxyprogesterone (1 mg) in ethanol (1 L).
0 The stock solution was diluted 100 times to give a working solution of
30 nmol/L.
0 Working standards were prepared by serial dilutions of the working solution
(0; 0.15; 0.3; 0.6; 1.2; 2.4; 4.8 nmol/L).
0 Aliquots (300 pi) of each standard solution were pipetted into appropriately
labelled plastic tubes, sealed and stored at -20°C.
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4.3.3 Salivary Androstenedione Standard Solutions
0 A stock solution of 3.5 pmol/l of androstenedione (molecular weight 286.0) was
made by dissolving 1 mg of androstenedione in 1 litre of ethanol. This is diluted
1000 times by adding 100 (J of stock solution to 100 ml of salivary assay diluent,
to give a solution of 3.5 nmol/L.
0 Working standards were prepared by serial dilutions of the working solution
(0; 0.018; 0.035; 0.07; 0.14; 0.28; 0.56; 1.12 nmol/L).
0 Aliquots (300 pi) of each standard solution were pipetted into appropriately
labelled plastic tubes, sealed and stored at -20°C.
4.3.4 Capillary Blood Spot Cortisol Standard Solutions
0 Using the original stock solution (500 pmol/L Cortisol in ethanol), a solution of
Cortisol in steroid hormone stripped serum was made (2000 nmol/L) by adding
200 pi of stock solution to 50 ml of stripped serum. This was used as the working
solution.
0 Working standards of Cortisol in stripped serum were then prepared by serial
dilution of the working solution (0; 50; 100; 200; 300; 400; 800; 1200; 1600; 2000
nmol/L).
0 Each of the above standard solutions is then double-diluted with washed red
blood cells to obtain the required blood spot standards (0; 25; 50; 100; 150; 200;
400; 600; 800; 1000 nmol/L).
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4.3.5 Preparation of washed red blood cells
0 Newly expired packed erythrocytes (160 ml) were divided equally into four
graduated polypropylene centrifuge tubes.
0 The tubes were centrifuged at 3000 r.p.m. for 20 minutes at 4°C.
0 The top layer of serum and erythrocytes was then aspirated, leaving 25 ml of
packed erythrocytes in each tube.
0 Isotonic saline (25 ml) was added to each tube. This was mixed well and
centrifuged again.
0 The supernatant was again aspirated and discarded.
0 The red cells were re-washed with saline and centrifuged once more.
0 The supernatant and the top layer of erythrocytes was aspirated once more,
leaving 15 ml of packed erythrocytes in each tube.
0 The aliquots of packed erythrocytes were pooled and mixed.
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160 mL newly expired packed erythrocytes
40 ml 40 ml 40 ml
50 ml graduated polypropylene centrifuge tubes
I
Centrifuge 3000 r.p.m. for 20 minutes, 4°C
I
Aspirate top layer of serum and erythrocytes
25 ml 25 ml 25 ml
40 ml
25 ml
Add 25 ml of isotonic saline and mix well
I
Centrifuge 3000 r.p.m. for 20 minutes, 4°C
Aspirate and discard supernatant
I
Repeat wash with 25 ml saline and centrifuge
I
Aspirate supernatant and top layer of erythrocytes
X
15 ml 15 ml
Pool and mix well
60 ml
Figure 4.1. Preparation of washed red blood cells.
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4.4 Salivary Steroid Assays
The salivary Cortisol, 17-OHP and androstenedione assays were performed using
the following common reagents, unless otherwise stated.
4.4.1 125l radiolabel
The radiolabel was potency checked and the solution diluted to 10,000 counts per
minute in salivary assay diluent.
4.4.2 Antibody preparation
Permeable Antibody-containing Micro-capsules (PAM) were used in the salivary
Cortisol assay (PAM 258), and in the salivary 17-OHP assay (PAM 259).
The salivary androstenedione assay employed a double antibody method.
4.4.3 Quality controls
Samples of saliva provided by healthy adult volunteers at various times of the day
were used as quality control samples. The samples were stored at -20°C and
thawed prior to use in the same way as the patient samples.
4.5 Salivary Cortisol Assay
4.5.1 Assay Procedure
0 All saliva samples were collected in clean dry plastic specimen containers and
frozen to -20°C. This denatured the glycoprotein.
The samples were thawed to room temperature and centrifuged at 2000 r.p.m. for
5 minutes. The clear supernatant was used for the assay.
0 Each standard (50 pi) and saliva sample (50 pi) was pipetted into duplicate
labelled tubes in the same way.
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0 125|- labelled Cortisol (100 pi at 10,000 c.p.m./tube) was added to each tube.
Total count tubes contained 100 pi of this reagent only.
0 Well-mixed PAM 258 antibody (200 pi of 1 in 50 dilution) was added to each
tube, except the total count tubes and non-specific binding (N.S.B.) tubes.
0 Duplicate N.S.B. samples in labelled tubes consist of 50 pi of assay diluent, 100
pi of 125l-cortisol, and 200 pi of PAM 247 (anti-thyroid antibody).
0 All tubes were vortex mixed and left to incubate at room temperature for VA
hours.
0 The total count tubes were put aside.
0 All other tubes were washed in wash solution, using the Watson-Marlow semi-
automated washing apparatus, then centrifuged at 2000 r.p.m. for 5 minutes.
This was repeated once (total of two times).
0 All tubes were counted using a multi-well gamma counter NE-1600.
The results were then calculated using the W.H.O. program for
radioimmunoassay and charted on log scale.
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Figure 4.2. Summary ofprocedure for radio-immunoassay of
Cortisol in saliva.
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4.6 Salivary 17-Hydroxyprogesterone Assay
4.6.1 Assay Procedure
0 The procedure for assay of 17-OHP was similar to the Cortisol assay, except for
the following:
125l- labelled 17-OHP (100 pi of 10,000 c.p.m./tube) was used.
Well-mixed PAM 259 antibody (200 pi of 1 in 50 dilution) was used.
Incubation time was 45 minutes.












100 \i\ 125|-17-OHP (10,000 c.p.m./tube)
+















Figure 4.3. Summary ofprocedure for radioimmunoassay of 17-
hydroxyprogesterone in saliva.
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4.7 Salivary Androstenedione Assay
4.7.1 Anti-androstenedione antibody.
First antibody rabbit A4-3-CMO-BSA (1 in 200,000).
(50 pi of antibody, pre-diluted to 1 in 2,000, in
50 ml of assay diluent.)
Second antibody donkey anti-rabbit antiserum (D.A.R.) with
N.R.S. (normalised rabbit serum) added.
(1 ml of D.A.R., 80 pi NRS in 20 ml of assay
diluent.)
4.7.2 Assay Procedure
0 All saliva samples were collected in clean dry plastic specimen containers and
frozen at -20°C.
The samples were thawed at room temperature and then centrifuged at 2000
r.p.m. for 5 minutes. The supernatant was used for the assay.
0 Each standard and saliva sample (100 pi) were transferred into duplicate labelled
tubes, using a manual pipette and Oxford tips.
0 Hexane-ether (3 ml of 4:1 mixture v/v) was added to the tubes and vortex-mixed
in a multi-tube vortexer for four minutes.
0 The lower aqueous phase of the mixture was then snap frozen by immersing the
lower part of the test tube in a bath of solid carbon dioxide and methanol.
0 The upper hexane:ether phase was carefully decanted into a glass tube. This
phase contains the extracted steroid.
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0 The solvent was then evaporated from all the tubes in a Buchler Vortex
evaporator.
0 125l- labelled androstenedione (100 pi of 10,000 c.p.m./tube) was added to each
tube.
Total count tubes contained 100 pi. of this reagent only.
0 First antibody (200 pi) was added to each tube, except the total count tubes and
non-specific binding (N.S.B.) tubes.
0 All tubes were vortex mixed and left to incubate at room temperature for at least 3
hours.
0 Second antibody (400 pi) was added to each tube. The mixture was again vortex
mixed and left to incubate overnight at 4°C.
0 The total count tubes were put aside. All other tubes were centrifuged at 3000
r.p.m. for 60 minutes. The supernatant was then aspirated from all tubes, leaving
the precipitate.
0 All tubes were counted using a multi-well gamma counter NE-1600. The results
were then calculated using the W.H.O. program for radioimmunoassay and
charted on log scale.




3 ml Hexaneiether (4:1 v/v)
Vortex mix for 4 minutes
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Figure 4.4. Procedure for radioimmunoassay of androstenedione in
saliva.
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4.8 Capillary Blood Spot Steroid Assays
The blood spot Cortisol, 17-OHP and androstenedione assays were performed using
the following common reagents, unless otherwise stated.
4.8.1 125l radiolabel
The radiolabel was potency checked and the solution diluted to 10,000 counts per
minute in salivary assay diluent.
4.8.2 Antibody preparation
Permeable Antibody-containing Micro-capsules (PAM) were used in the blood spot
Cortisol assay (PAM 258), and in the blood spot 17-OHP assay (PAM 259). The
antibodies were stored at 4°C.
The blood spot androstenedione assay employed a double antibody method.
4.8.3 Quality controls
Capillary blood spot samples provided by healthy adult volunteers at various times
of the day were used as quality control samples. The samples were stored at room
temperature and used in the same way as the patient samples.
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4.9 Capillary Blood Spot Cortisol Assay
4.9.1 Anti-cortisol antibody - stored at 4 °C
PAM 258 - 1 in 50 dilution.
4.9.2 Assay Procedure
0 All capillary samples were collected on filter paper and stored at room
temperature. All test tubes were prepared in duplicate and labelled.
0 Two 2.5 mm diameter discs (equivalent to 6 pi of whole blood) were punched out
of the filter paper with standard solutions. Citrate/phosphate buffer (100 pi) was
added as eluting fluid.
0 Capillary blood spot samples were punched into labelled paired tubes in the
same way, and 100 pi of citrate/phosphate buffer is added to each tube.
0 125l- labelled Cortisol (100 pi of 10,000 c.p.m./tube) was added to each tube.
Total count tubes contained 100 pi of label only.
0 Well-mixed PAM 258 (200 pi of 1 in 50 dilution) was added to each tube, except
the total count tubes and non-specific binding (N.S.B.) tubes.
0 Duplicate N.S.B. samples in labelled tubes consist of 100 pi of citrate/phosphate
buffer and a punched out disc of blank filter paper. 100 pi of 125l-cortisol, and 200
pi of PAM 247 (anti-thyroid antibody) used as N.S.B.
0 All tubes were vortex mixed and left to incubate at room temperature overnight.
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0 The total count tubes were put aside.
All other tubes were washed with a solution of gel in saline, using the Watson-
Marlow semi-automated washing apparatus, then centrifuged at 2000 r.p.m. for 5
minutes. This was repeated once (total of two times).
0 All tubes were counted using a multi-well gamma counter NE-1600.
The results were then calculated using the W.H.O. program for radio¬
immunoassay and charted on log scale.




2.5 mm disc x2 2.5 mm disc x2
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100 pi cit/phos. buffer 100 pi cit/phos. buffer
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I
100 pi 125|-CORTISOL (10,000 c.p.m./tube)
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2000 r.p.m. 5 minutes
repeat wash/spin cycle
COUNT AND CALCULATE
Figure 4.5. Procedure for radio-immunoassay of Cortisol in
capillary blood spot samples.
106
5 Development of Steroid Assays
5.1 Introduction
The aims of the project were to develop assay procedures for measuring steroids in
saliva, a facility not at that time available in the regional endocrine laboratory. The
three steroids to be assayed were Cortisol, 17-hydroxyprogesterone (17-OHP) and
androstenedione. The assay procedures needed to be relatively simple to perform,
requiring minimal training. Ideally they would have a relatively rapid turnover time
since they were to be used as a screening method for detecting low steroid levels in
a large numbers of samples. They should also be sensitive and specific.
A capillary blood spot 17-OHP assay was already in use in the regional laboratory
for monitoring patients with congenital adrenal hyperplasia. It was felt that this
sensitive assay could be adapted for 17-OHP measurement in saliva. The same
applied to a capillary blood spot androstenedione assay, which had recently been
developed in the laboratory. By contrast a capillary Cortisol assay was not
established in the laboratory so that both blood spot and salivary Cortisol assays
needed to be developed.
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5.2 Salivary Cortisol Assay Development
5.2.1 Introduction
The initial problem in developing the Cortisol assays was the antibody selection.
Initial experiments involved the use of a donkey anti-sheep Cortisol antibody using a
double antibody technique as a reference experiment. This was found to have a low
sensitivity for the purposes of the study. The highly sensitive Cortisol antibody
developed by Chearskul (Chearskull 1985), was in short supply, so we had to find
an alternative.
5.2.2 Antibody sensitivity and dilution in Salivary Cortisol
Assays
The initial double antibody radioimmunoassay of salivary Cortisol was performed
using Cortisol antibody from Scottish antibody production unit (SAPU). This antibody
was available in reasonably large quantities and was used for the regional
laboratory routine serum Cortisol assay.
An antibody dilution curve was constructed using dilutions ranging from 1 in 50 to 1
in 204,800 were used. The assay was performed by adding 200 pi of Cortisol label
into duplicate labelled tubes. To each pair of tubes, 200 pi of antibody was added.
After vortex mixing and incubating for two hours, donkey anti-sheep antibody (from
SAPU) was added (400 ml) to each tube and incubated overnight at 4°C. The tubes
were then centrifuged the following day at 3,000 r.p.m. for 45 minutes at 4°C. The
supernatant was then removed by suction and the precipitates counted in a multi-
well gamma counter (NE-1600). The results were then plotted on a chart (Fig. 5.1).
The results showed that high concentrations of antibody inhibit antibody-cortisol
binding, and with progressively lower antibody concentrations, the binding affinity
increased, reaching a peak of 89% before falling exponentially.
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The experiment was repeated by adding 1,000 nmol/L of Cortisol in ethanol to each
tube. The ethanol was evaporated to dryness before adding label and antibody.
Antibody dilutions between 1 in 800 and 1 in 51,200 were used.
A Kelly curve was then constructed (Fig. 5.2). From this, an antibody concentration
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Antibody dilution (x10-1)
Fig. 5.1. Antibody dilution curve using SAPU antibody to determine optimal antibody
dilution
100 1000 10000 100000
Antibody Dilution (x101)
Fig. 5.2. Kelly curve using SAPU antibody; to determine the sensitivity range of the
assay.
5.2.3 Standard Curve using Second Antibody Technique
Using the optimal antibody concentration described above, a standard curve was
constructed for Cortisol in ethanol. Concentrations from 0 to 1,000 nmol/L were
used, including concentrations of 1.25, 2.5 and 10 nmol/L.
Each Cortisol standard solution (50 pi) was added to paired tubes, and the ethanol
evaporated off. The Cortisol label and antibody were then added as before and the
tubes incubated in the same way.
A standard curve of percentage binding against Cortisol concentration was
constructed. From this, the assay sensitivity was calculated to be 2.2 nmol/L
(calculated by finding the concentration of Cortisol required to produce a 10% drop in
%B/Bo from 100% (at a concentration of 0 nmol/L).
5.2.4 Standard Curve using Capsulated Antibody
The donkey anti-rabbit antibody from SAPU was encapsulated (PAM 251) and a
standard curve constructed. The Cortisol antibody was encapsulated using the
method by Wallace and Wood (Wallace & Wood 1984). Cortisol standards (range 0
to 1,000 nmol/L) were placed in duplicate tubes as before, and the ethanol
evaporated off. Cortisol label (200 pi) was added to each tube along with capsulated
antibody (200 pi). The tubes were vortex-mixed and left to incubate at room
temperature for 90 minutes. The tubes were then washed in gel-saline and
centrifuged at 2,000 r.p.m. for 5 minutes. The supernatant was aspirated, the wash
cycle repeated, and the tubes, counted in a multi-well counter (NE-1600). The
results were used to construct a standard curve. From this, the sensitivity of the
assay was calculated, and found to be 1.7 nmol/L. This was more sensitive than the
double antibody method. The use of PAM 251 in the assays was therefore
developed further.
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A salivary Cortisol standard curve was then constructed in the same way as above,
using PAM 251, but this time with Cortisol standard concentrations ranged from 0 to
32 nmol/L. The standards were made in salivary assay diluent; 100 pi of each
standard was placed in duplicate tubes, with 100 pi of Cortisol label. The standard
curves with ethanolic standards and salivary standards were compared. The
standard curves were the same, indicating that cortisol-antibody binding was not
affected by using salivary assay diluent.
In total, 10 assays were performed using PAM 251. The sensitivity for these assays
was 1.2 nmol/L.
5.2.5 Comparison of Different Cortisol Antibodies for Salivary
Assays
The levels of sensitivity obtained were felt to be too high for the purposes of this
study. From the earlier work performed by Chearskull, (Chearskull 1985) it was
known that PAM 253 (Cardiff antibody) was very sensitive, but unfortunately in short
supply. The standard curve using this antibody was compared with PAM 251, and
also with PAM 254, an antibody more readily available and in large supply.
Initial antibody dilution curves using 100pl volumes of standards suggested a
dilution of 1 in 50 for PAM 253 and 1 in 100 for PAM 254. From the results, PAM
253 was found to give the most sensitive results, as expected. However, PAM 254
also gave acceptable results, with sensitivity below 1 nmol/L. The assay was
therefore developed using this antibody (Figs. 5.3; 5.4; 5.5).
The assay sensitivity remained at 0.9 nmol/L in several assays performed
(n = 15).
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5.2.6 Comparison of Different Antibody Preparations and
Concentrations
Standard curves using different antibody preparations were compared with PAM 253
and PAM 254. Two different preparations of Guildhay Cortisol antibody were made.
These were made by using lower concentrations of Guildhay antibody
(400 pi and 100 pi) at the stage of encapsulation. These were named PAM 255 and
PAM 256. The results of the standard curves were compared with PAM 253 and
PAM 254. (Figs. 5.4; 5.5)The standard curve using PAM 256 was improved




5.2.7 Comparison of Different concentrations of Antibody and
Standard Volumes
Using PAM 256 to construct standard curves, antibody dilutions of 1 in 50 and 1 in
100 were compared, together with sample volumes of 50 pi and 100 pi. An Antibody
dilution of 1 in 100, and sample volume of 50 pi gave the best sensitivity and
specificity. From a total of 15 assays, the sensitivity remained constant at 0.9nmol/L.
Unfortunately, when further supplies of antibody were obtained, antibody from a
different bleed was provided. Further assays showed that the antibody sensitivity
was different from the original work done. The assay sensitivity with PAM 258 was
1.5nmol/L. By repeating the standard curves with different antibody concentrations
(PAM 257, PAM 258, made on separate occasions), it was found that the optimum
antibody concentration was using PAM 258 at a dilution of 1 in 50. (Figs. 5.6; 5.7)
The assay sensitivity with this antibody dilution was 0.9nmol/L, the same as the
original sensitivity with the earlier encapsulated antibody.
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5.2.8 Recovery Experiments for Salivary Cortisol Assay
Recovery experiments were performed by adding known amounts of Cortisol in
different concentrations (low and high) to samples of saliva of different concentration
from healthy adult volunteers. Recovery of Cortisol was calculated as a percentage
by dividing the actual concentration measured by the expected concentration. The
recovery of Cortisol when low concentrations of Cortisol was added was 96% and
113% in the low and high samples, and when high concentrations were added, the
recovery was 111 % and 94%.
5.2.9 Cross-reactivity Experiments
Cross-reactivity of Cortisol to corticosterone, cortisone, prednisolone,
17-hydroxyprogesterone and 6-p-hydroxycortisol was determined in the salivary
Cortisol assay using PAM 258 antibody preparation using the method described by
Abraham (Abraham 1969). These steroids were chosen in particular for two
reasons: these steroids were important in saliva as they were present in significant
amounts: the cross-reactivity figures of studies performed by the producers of the
antibody suggesting that these steroid hormones produced significant cross-reaction
with Cortisol.
Each steroid was dissolved in ethanol to give a stock solution of 100pg/ml (1mg of
steroid was dissolved in 10ml of ethanol). Following this, 1 ml of the stock standard
solution for each steroid was diluted with ethanol (99 ml), to give an intermediate
solution of 1pg/ml. These solutions were stored at 4°C until needed. Dose response
curves were then derived for each competing steroid and compared with the Cortisol
dose response curve.
The standard curves were constructed and the mass of each competing steroid
needed to displace 50% of the bound labelled Cortisol was determined. Cross-
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reactions were calculated for each of the steroids and the results are shown in Table
5.1. These results were compared with those obtained by the producers of the
antibody.
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Steroid Cross-reactivity for Cross-reactivity






Table 5.1. Results of cross-reactivity experiments with salivary
Cortisol assay, using PAM 258, comparing results obtained by
Guildhay laboratories.
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5.2.10 Summary of Salivary Cortisol Assay Development
Salivary Cortisol assay was developed initially using SAPU Cortisol antibody.
However, this was found to have a sensitivity of not less than 1.2nmol/L. This was
felt to be inadequate for the purposes of this project in being able to detect low
levels of Cortisol in saliva. A more sensitive assay was developed with an antibody
from Guildhay laboratories (PAM 258). Using various antibody dilutions and sample
sizes, the optimum combination was found which gave good sensitivities and also
good duplication of sample results. The final assay gave a sensitivity of 0.9 nmol/L,
using an antibody dilution of 1 in 50 and sample sizes of 50 pi.
The coefficient of variation of the assay was 9% for intra-assay variation, and 12%
for inter-assay variation for both high and low concentrations.
5.3 Salivary 17-Hydroxyprogesterone Assay
Development
The salivary 17-OHP assay developed for this study was adapted from a previously
developed capillary blood spot assay (Chearskull 1985). Using similar sample and
standard volumes, incubation times and wash methods (as described earlier), and
using PAM 259, the standard antibody used in the laboratory for routine serum and
17-OHP blood spot estimations, a standard curve was obtained which was adequate
for use in salivary 17-OHP estimations. The assay sensitivity was 0.1 nmol/L.
5.4 Salivary Androstenedione Assay Development
There has been little published work to date on the measurement of
androstenedione in saliva in normal children. Assay of androstenedione in serum
121
and blood spot samples has come across problems with the presence of steroid
conjugates that interfered with the assay. The main decision with salivary
androstenedione measurement was whether an extraction step was necessary.
5.4.1 Comparison of extraction assay and direct
androstenedione assay for Salivary Androstenedione
Comparison of standard curves from extraction assay and direct assay, showed no
significant difference in standard curves (Figs. 5.8; 5.9). There was a slight
reduction in assay sensitivity between extraction and direct assay (44 pmol/l and 27
pmol/l). However, measurement of androstenedione in saliva samples resulted in
much higher values being obtained by the extraction assay compared to the direct
method, as has been described previously (Thomson 1991).
122
Androstenedione concn. (nmol/l)
Fig. 5.8. Salivary androstenedione assay. Comparison of direct and extraction
assays.
Androstenedione concn. (nmol/l)
Fig. 5.9. Salivary androstenedione standard curves. Comparison of %B/Bo against
androstenedione concentration for extraction and direct assays.
5.4.2 Comparison of standard curves for Salivary
Androstenedione using different sample volumes
Comparing standard curves using 50 pi and 100 pi samples, it was noted that the
sensitivity was reduced using the smaller volume size.
5.4.3 Antibody dilution curve for androstenedione assay
A modified Kelly curve was constructed using the same method as for the Cortisol
assay. From this, an antibody dilution of 1 in 200,000 was found to give optimal
performance for the salivary androstenedione standard curve. Using this antibody
dilution and extraction method, the final assay sensitivity was 35pmol/L.
5.5 Capillary Blood Spot Cortisol Assay Development
5.5.1 Introduction
Development of the capillary blood spot assay had several different problems to the
salivary Cortisol assay. One of the main problems was that of cortisol-protein
binding, and more specifically of protein-binding inhibition. Once this was overcome,
the next problem was optimising the assay for use on blood spot samples.
Much initial development work was performed with the salivary Cortisol assay in
relation to antibody selection.
5.5.2 Standard Curve for capillary Cortisol using Different
Concentrations of ANS
The standard curves were constructed using various concentrations of ANS (0
mg/ml, 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 5 mg/ml and 10 mg/ml).
This was used as a protein-binding inhibitor. ANS generally reduced the antibody
binding and lowered the sensitivity to an unacceptable level. A concentration of 1
mg/ml of ANS gave the optimum results in terms of sensitivity.
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5.5.3 Comparison of ANS with Citrate/phosphate buffer in
capillary Cortisol assay
Standard curves were plotted using RIA buffer with ANS and citrate/phosphate
buffer (Figs. 5.10; 5.11). It was found that citrate/phosphate buffer interfered less
with antibody binding, and also improved sensitivity of the assay.
From the results, it was deduced that the use of citrate/phosphate buffer was the
optimal buffer for sensitivity. This was therefore used in further development of the
capillary blood spot assay.
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Cortisol concn (nmol/l)
Fig. 5.11. Effects of Citrate/phosphate Buffer and ANS on Capillary
Cortisol Standard Curve - %B/Bo against Cortisol concn. for PAM 256
Citrate/phosphate
ANS 1mg/ml
5.5.4 Comparison of different antibody dilutions, eluting fluid
volumes and antibody preparations for capillary Cortisol
assay
A dilution of PAM 251 of 1 in 50 and 1 in 100 were compared. It was found that the
standard curves were very similar, although there was slightly improved sensitivity
when a dilution of 1 in 50 was used. When different volumes of eluting fluid were
compared, the standard curve that employed 100 pi of eluting fluid gave the most
sensitive standard curve. When comparing PAM 251, PAM 256, PAM 257 and PAM
258, the standard curves for each antibody preparation were very similar, with very
little difference in sensitivities.
5.5.5 Comparison of standard curves at different
temperatures and incubation times for capillary Cortisol
The assay was repeated by initially eluting the samples overnight and then adding
Cortisol label and antibody the next day. This was then left to incubate for 1.5, and 3
hours at room temperature, and the results compared. The standard curve showed
very poor sensitivity.
The assay was repeated, but the tubes were incubated at 37°C. The sensitivity did
improve but still remained inadequate for the purposes of the study.
The assay was again repeated, but all reagents and eluting fluid were added to the
tubes at the same time, the tubes were vortex-mixed, and left to incubate overnight
at room temperature. The result of this was to increase antibody-cortisol binding and
also to improve sensitivity to around 20 nmol/L whole blood.
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5.5.6 Comparison of standard curves for capillary Cortisol
assay constructed from standard blood spot samples of
different ages
Five standard curves were constructed using standard blood spot samples of
varying ages. These were then compared (Figs. 5.12; 5.13). The standard curves
were very similar, with very little difference in sensitivity, suggesting that the Cortisol
in the blood spot remains stable over time.
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5.5.7 Summary of capillary blood spot Cortisol assay
development
The blood spot Cortisol assay was developed from the salivary assay. There were
more problems relating to antibody binding with this assay, as a consequence of the
presence of Cortisol binding globulin. The use of protein binding inhibitors to release
Cortisol from its binding protein also resulted in a significant reduction of antibody
binding, particularly with ANS. This was partly resolved by the use of
citrate/phosphate buffer at pH 4.0, and also by greatly prolonging incubation time by
eluting with all the reagents overnight. The final assay had a sensitivity of 20 nmol/L
whole blood (equivalent to 40 nmol/L serum).
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6 Results
6.1 Control Population Data
Out of 340 schoolchildren whose parents gave consent, 172 (49%) subjects (91
girls, 77 boys) aged between 5 and 15 years provided up to six samples of saliva
over a 24 hour period, at predetermined times (08:00, 11:00, 17:00, 20:00, 23:00,
and 08:00 hours the following day). Of the 172 profiles, 21 (12.5%) were unsuitable
for inclusion into the study because the samples were either too small in volume, or
were blood-stained, or contained a significant amount of foreign material, e.g. food,
on visual examination. A further four children were unable to provide adequate
volumes of saliva. Therefore, 147 profiles (77 from girls, 70 from boys) were suitable
for the study. The majority of the profiles were from primary schoolchildren (129)
with only 18 samples from the secondary schoolchildren.
The median age of the boys in the control group at the time the profiles were taken
was 8.9 years (range 5.0 to 13.6 years), and the median age for the girls was 10.0
years (range 5.3 to 14.4 years).
The heights and weights of the 77 female controls (Fig. 6.1, Fig. 6.2) and the 70
boys (Fig. 6.3, Fig. 6.4) who took part in the study were plotted against age and
found to be comparable to the latest British height and weight reference charts.
(Freeman et al 1995).
75 children (51%: 45 girls, 30 boys) provided 6 samples of saliva in 24 hours.
65 children (44%: 27 girls, 38 boys) provided 5 samples of saliva in 24 hours.
7 children (5%: 5 giris, 2 boys) provided up to 4 samples of saliva in 24 hours. Each
sample of saliva was assayed for Cortisol, 17-OHP, and androstenedione.
131
The maximum 8 a.m. concentrations, minimum concentrations, maximum/minimum
ratio and area under the curve (AUC) for the 24 hour profiles were each plotted
against age, body surface area, and body mass index for each steroid assayed.
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6.2 Patient Group Data
A total of 43 patients were suitable to be entered into the study. Thirty six patients
provided samples of saliva. Fourteen patients (7 girls, 7 boys) provided salivary
profiles when they were well and when they were unwell with an intercurrent illness.
This was defined as a pyrexia of at least 38°C, and/or preventing them from going to
school.
Thirty two patients (13 girls, 19 boys) also provided capillary blood spot samples at
the same time as the salivary samples. Four of the patients preferred blood spot
sampling to saliva collection, saying that collecting saliva was more difficult to
perform, and took longer to collect.
Of these, 13 were patients with leukaemia (10 boys, 3 girls), and 20 were brain
tumour survivors (8 boys, 12 girls). One boy had a B cell lymphoma, one boy a
neuroblastoma and one boy a rhabdomyosarcoma of the jaw. All patients who took
part were considered to be at risk of developing SAI owing to the dose of cranial
irradiation they had received. A large proportion of these patients already had
documented evidence of hypothalamo-pituitary dysfunction. Tables 6.1 and 6.2
show the different diagnostic groups of patients entered into the study together with
details of the dose of cranial irradiation used and the calculated total dose to the










































































































































































































































































Table6.2.Malstudyp ientsindr allateffectss udy
6.3 Salivary Steroid Profiles
6.3.1 Control Group
6.3.1.1 Salivary Cortisol
A diurnal variation of salivary Cortisol was noted in all profiles (See Fig. 6.5). In all
the profiles received, a peak salivary Cortisol value was obtained in at least one of
the 8 a.m. samples. The median morning salivary Cortisol concentration was 14.5
nmol/L (reference range of 2.5% to 97.5%, 6.5 - 28.1 nmol/L). The median minimum
salivary Cortisol concentration (11 p.m.) was 1.4 nmol/L (reference range, 2.5% to
97.5%, <0.9 - 5.1 nmol/L) (See Fig. 6.6). Using the Mann-Whitney non-parametric
test, no sex difference was demonstrated for salivary Cortisol concentration.
There was no correlation between age and maximum salivary Cortisol concentration
(r = -0.127, p =0.176), minimum Cortisol concentration (r = 0.044, p =0.393),
maximum/minimum Cortisol ratios (r = 0.015, p =0.278), and AUC (r = -0.048, p
=0.170). There was also no correlation when similar curves were plotted against
body surface area, and body mass index.
38 samples were found to have salivary Cortisol concentrations below the limit of
sensitivity of the assay (0.9nmol/L). These samples were taken either in the late
afternoon or evening, whereas all morning samples had detectable Cortisol
concentrations.
In 138 of the profiles, two consecutive 8 a.m. samples were obtained. Comparing
these two groups revealed that there were similar results in both groups.
Median values were 12.2 and 10.3 mmol/L respectively, and the standard deviation
was 5.8 and 6.1 respectively. The two groups also had a similar spread of results
(minimum values were 1.0 and 1.3 mmol/L; maximum values were 30.4 and 35.9
mmol/L respectively). The correlation coefficient for the two groups was 0.16.
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Table6.3.SalivaryCortisolconcen rations(inmol/L)ihe l hy childrenaged5to15yea s(n—147))
6.3.1.2 Salivary 17-Hydroxyprogesterone
A diurnal variation was noted in the salivary 17-OHP profiles. (Figs. 6.7, 6.8).
There was a small but significant difference in maximum salivary
17-OHP concentration between girls and boys in the control group
(p = 0.0142). The median peak morning salivary 17-OHP concentration was 0.3
nmol/L for girls and 0.2 nmol/L for boys (Fig. 6.9). In girls, maximum salivary 17-
OHP concentration rose significantly with age. However, this was only just within the
level of significance (r = 0.232, p = 0.044; Fig. 6.10). No correlation was found
between peak morning salivary 17-OHP and either body mass index (r = 0.096, p =
0.411), or body surface area (r = 0.096, p = 0.058).
In boys, no correlation was found between peak morning 17-OHP concentration and
either age, body surface area (r = 0.178, p = 0.159) or body mass index (r = 0.046, p
= 0.717). 17-OHP concentration did rise with age, but the correlation was only just
out with the level of statistical significance (r = 0.243, p = 0.053) (Fig. 6.11). There
was also a significant difference in maximum/minimum ratios between girls and boys
(p = 0.0074). There was no sex difference for AUC for 17-OHP profiles (p = 0.11)
nor for minimum salivary 17-OHP concentration (p = 0.12). Using the salivary 17-
OHP data obtained from the control group, an age-related reference range was
defined for males and females up to 15 years of age (Table 6.4).
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Female controls (Total = 76)
Fig. 6.7. Age distribution of median salivary 17-hydroxyprogesterone profiles in female controls
Male controls (Total = 65)
Time of Day
Fig. 6.8. Age distribution of median salivary 17-hydroxyprogesterone profiles in male controls.
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Minimum salivary 17-OHP concentration was below the limit of sensitivity of the
assay (0.1 nmol/L) in 55 out of 76 girls, and 52 out of 65 boys.
In girls, the peak morning salivary 17-OHP concentration correlated well with age (r
= 0.367, p = 0.001) and body surface area (r = 0.283, p = 0.013), but not with body
mass index (r = 0.106, p = 0.363). Stepwise regression analysis showed that age
was the most important predictor.
In boys, no such correlation was found.
In girls a significant correlation was found between AUC for salivary 17-OHP profiles
and age (r = 0.267, p = 0.026) and body surface area (r = 0.244, p = 0.042) but not
body mass index (r = 0.136, p = 0.261).
In boys no such correlation was found.
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6.3.1.3 Salivary Androstenedione
A diurnal variation was also noted in the salivary androstenedione profiles (Figs.
6.12; 6.13), and values were also found to rise with age. There was a significant
difference between female and male maximum salivary androstenedione
concentrations (p = 0.0084). The median maximum concentrations were 0.4nmol/L
for girls and 0.3nmol/L for boys (Fig. 6.14). In girls there was a significant
relationship between maximum salivary androstenedione concentration and age,
body surface area and body mass index (r = 0.571, p<0.001; r = 0.552, p<0.001; r =
0.385, p=0.001, respectively). Using stepwise regression analysis, the main
predictor was found to be age (Fig. 6.15).
In boys, no such relationship was found (Fig. 6.16).
There was also a significant difference in AUC for boys and girls (p = 0.0124). The
median value for girls was 4.7, for boys it was 3.3. There was no significant
difference between girls and boys for maximum/minimum salivary androstenedione
ratios and minimum salivary androstenedione concentrations. In girls, there was
also a significant correlation between minimum salivary androstenedione
concentration and age (r = 0.548, p<0.001), body surface area (r = 0.586, p<0.001),
and body mass index (r = 0.463, p<0.001). Using stepwise regression analysis, the
main predictor was found to be body surface area. This correlation was not noted in
boys (age: r = 0.113, p = 0.353; body surface area: r = 0.074, p = 0.550; body mass
index: r = 0.081, p = 0.511).
There was a significant correlation between AUC for salivary androstenedione
profiles and age (r = 0.575, p<0.001), body surface area (r = 0.580, p<0.001), and
body mass index (r = 0.455, p<0.001). Using stepwise regression analysis, the main
predictor was found to be body surface area.
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In boys, no correlation was found between AUC and either age (r = 0.185, p =
0.144), body surface area (r = 0.062, p = 0.629), or body mass index (r = 0.002, p =
0.988).
Using the salivary 17-OHP data obtained from the control group, an age-related
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Fig. 6.13. Age distribution of median salivary androstenedione profiles in male controls.
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Fig. 6.15. Maximum salivary androstenedione concentration against age in female controls
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6.3.2 Salivary Steroid Ratios
Ratios of Cortisol to 17-OHP, Cortisol to androstenedione and 17-OHP to
androstenedione, were calculated for each maximum and minimum salivary Cortisol
concentration for each control subject.
The aim was to determine the relative change in salivary steroid levels at peak and
trough Cortisol concentrations, to assess whether this may be of value in detecting
hypoadrenalism. We hypothesised that in SAI, 17-OHP is "shunted" down the
Cortisol pathway to maximise Cortisol output at the expense of androstenedione
production, so the cortisol/17-OHP or cortisol/androstenedione ratios will rise.
The results were then plotted against age, body surface area and body mass index.
For minimum concentrations that were below the limit of sensitivity of the assays the
concentration was taken as that limit (i.e. 0.9nmol/L for salivary Cortisol).
6.3.2.1.1 Salivary Cortisol/17-Hydroxyprogesterone Ratios
In girls, there was no significant correlation between the cortisol/17-OHP ratios at
maximum salivary Cortisol concentration and any of the parameters above (age: r = -
0.178, p = 0.126, figure 6.17; body surface area: r = -0.221, p = 0.056; body mass
index: r = -0.202, p = 0.082). The median value at maximum salivary Cortisol
concentration in girls was 55.6 (range 19.9 - 397.5).
In boys, there was a significant but weak negative correlation between the ratios at
maximum salivary Cortisol concentration and body surface area (r = -0.25, p= 0.042;
figure 6.18). The ratios decreased with increasing body size. The median value at
maximum salivary Cortisol concentration in boys was 57.5 (range 9.9 - 273.8).
Otherwise there was no significant correlation found between age (r = -0.133, p =
0.285) and body mass index (r = -0.202, p = 0.102).
For ratios at minimum salivary Cortisol concentration, there was no correlation found
for either boys and girls between the ratios at minimum salivary Cortisol
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concentration and age (girls: r = -0.008, p =0.943; boys: r =-0.011, p = 0.932), body
surface area (girls: r = 0.089, p = 0.448; boys: r = -0.183, p = 0.137), and body mass
index (girls: r = 0.081, p = 0.489; boys: r = -0.146, p = 0.238).
The median value at minimum salivary Cortisol concentration in girls was 12 (range
3.2 to 57). In boys the median value was also 12 (range 3.9 to 154).
Using the Mann-Whitney test, there was no sex difference between the cortisol/17-











Female controls (n = 76)
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Age (years)
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r =-0.178 (p= 0.126)
Fig. 6.17. Cortisol/17-hydroxyprogesterone ratio against age at maximum salivary Cortisol
concentration - female controls
Body surface area (m2)
Male controls (n = 67) r = -0.250 (p=0.042)
Fig. 6.18. Cortisol/17-hydroxyprogeste rone ratio against body surface area for maximum salivary
Cortisol concentration - male controls
Salivary Cortisol/Androstenedione Ratios
In girls, there was significant negative correlation between salivary
cortisol/androstenedione ratios at maximum salivary Cortisol concentration and age
(r = -0.539, p<0.001, figure 6.19), body surface area
(r = -0.423, p<0.001), and body mass index (r = -0.254, p = 0.026). Using stepwise
regression analysis, age was found to be the main predictor.
The median value at maximum salivary Cortisol concentration in girls was 3.8 (range
1.2 to 15.7).
In girls there was also significant negative correlation between salivary
cortisol/androstenedione ratios at minimum salivary Cortisol concentration and age (r
= -0.270, p = 0.018, figure 6.20), but not body surface area (r = -0.184,p = 0.111),
nor body mass index (r = -0.095, p = 0.414).
The median value at minimum salivary Cortisol concentration in girls was 2.2 (range
Oto 18).
In boys, there was no correlation found between ratios at maximum salivary Cortisol
concentration and either age (r = -0.140, p = 0.264), body surface area (r = -0.044, p
= 0.727), or body mass index (r = 0.010, p = 0.940), and minimum salivary Cortisol
concentration and either age (r = 0.132, p = 0.290), body surface area (r = 0.069, p
= 0.587), or body mass index (r = -0.067, p = 0.595).
The median value at maximum salivary Cortisol concentration in boys was 4.0
(range 1.5 to 29.6). The median value at minimum salivary Cortisol concentration in
boys was 3.2 (range 0 to 40).
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Fig. 6.19. Cortisol/androstenedione ratio against age against maximum salivary Cortisol
concentration in female controls.
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Female controls (n = 75)
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r =-0.270 (p = 0.018)




No correlation was found in boys between salivary 17-OHP/androstenedione ratios
and age, body surface area and body mass index.
In girls, there was significant negative correlation between salivary 17-
OHP/androstenedione ratios at maximum salivary Cortisol concentration and age (r
= -0.397, p<0.001, figure 6.21; c.f. boys: r = -0.077, p = 0.525, figure 6.22), and
body surface area (r = -0.288, p =0.012; c.f. boys: r = 0.068, p = 0.578), but not body
mass index (r = -0.187, p = 0.106; c.f. boys: r = 0.139, p = 0.250).
The median value at maximum salivary Cortisol concentration in girls was 0.06
(range 0.01 to 0.3). The median value in boys was 0.05 (range 0 to 0.52).
In girls, there was significant negative correlation between salivary 17-
OHP/androstenedione ratios at minimum salivary Cortisol concentration and age (r =
-0.459, p<0.001, figure 6.23; c.f. boys: r = 0.043, p = 0.725, figure 6.24), body
surface area (r = -0.453, p<0.001;c.f. boys: r = 0.101, p = 0.406), and body mass
index (r = -0.319, p = 0.005; c.f. boys: r = 0.056, p = 0.647). No such correlation was
found in boys.
Using stepwise regression analysis, the main predictor in girls was age for ratios at
maximum and minimum salivary Cortisol concentration.
The median value at minimum salivary Cortisol concentration in girls was 0.19
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Female controls (n = 76)
14 15
r = -0.397 (p<0.001)
Fig. 6.21. 17-hydroxyprogesterone/androstenedione ratio against age for maximum salivary Cortisol











9 10 11 12 13
Age (years)
14 15
Male controls (n = 70) r = -0.077 (p = 0.525)
Fig. 6.22. 17-hydroxyprogesterone/androstenedione ratio against age for maximum salivary Cortisol
concentration in male controls.
Female controls (n = 76) r=-0.459 (p<0.001)
Fig. 6.23. 17-hydroxyprogesterone/androstenedione ratio against age for minimum salivary Cortisol
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Male controls (n = 70) r = 0.043 (p = 0.725)
Fig. 6.24. 17-hydroxyprogesterone/androstenedione ratio against age for minimum salivary Cortisol
concentration in male controls.
6.3.3 Summary of Steroid Profile Results in Controls
0 All three steroids exhibited a diurnal rhythm, but with a wide variation in salivary
steroid concentrations. The minimum concentrations were often undetectable.
0 No correlation was found between salivary Cortisol concentrations and age, body
surface area or body mass index, in the age range studied, nor was there a
demonstrable sex difference.
0 A measurable morning salivary Cortisol concentration was found in all control
profiles.
0 Both salivary 17-OHP and androstenedione concentrations were higher in girls
than in boys.
0 Salivary 17-OHP and androstenedione concentrations rose with age in girls;
statistical correlation was not demonstrated in boys.
0 It was not possible to determine whether the rise in 17-OHP and
androstenedione was gradual or whether it occurred in relation to the onset of
adrenarche and puberty.
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6.3.4 Summary of Results of Salivary Steroid Ratios
0 There was no correlation demonstrated for the ratios of salivary Cortisol to 17-
OHP at both maximum and minimum salivary Cortisol concentrations and age,
sex, weight or body mass index.
0 The ratios of Cortisol to androstenedione demonstrated a significant negative
correlation at maximum and minimum salivary Cortisol concentrations in girls with
age as the main predictor. This was not the case in boys where no correlation
was found.
This suggests that there is a greater rise in androstenedione concentration than
Cortisol concentration in girls with advancing age.
0 The ratios of 17-OHP to androstenedione in saliva failed to demonstrate any
relationship in boys. However, in girls, there was a significant negative correlation
at both maximum and minimum salivary Cortisol concentrations for age.
This suggests that there is an increase in androstenedione concentration relative
to 17-OHP with advancing age in girls.
164
6.3.5 Salivary steroids in the study patient group (basal and
stressed)
The maximum salivary steroid hormone concentration was compared, as was the
minimum salivary steroid concentration, the area under the curve for each steroid
hormone profile, and the maximum/minimum ratio of the steroid hormones
measured.
6.3.5.1 Salivary Cortisol Profiles (see Figure 6.29 and Tables 6.6
and 6.7)
All except two patients showed a diurnal variation of Cortisol in saliva (G05 and B16,
Figures 6.25, 6.26 respectively). These patients had flat profiles with concentrations
of salivary Cortisol below the limit of sensitivity. A further two patients had salivary
Cortisol concentrations at the lower end of the normal range (B18 and G10, Figs.
6.27 and 6.28 respectively). The remainder of the study patient profiles all had
salivary Cortisol levels within the reference range of the control children (Fig. 6.29).
The median maximum basal salivary Cortisol concentration in the study patients
(excluding the two abnormal profiles) was 15.7 nmol/L (range 9.2 to 20.5 nmol/L),
similar to the control value (median 14.5 nmol/L, range 10.3 to 18.2). The median
minimum basal salivary Cortisol concentration (excluding the abnormal profiles) was
2.5nmol/L (range 1.7 to 3nmol/L), not different form the control median value of 1.4
(range <0.9 to 16.3 nmol/L).
Table 6.6 shows the raw data of salivary steroid results for the female study patient






















































































































































































































































































































































































































































































































































































































































































































































Table6.7.SalivaryteroidResultsinM lest yp t entadrenalateffectss udy
In some patients who had provided basal and stressed salivary profiles, there was a
rise in salivary Cortisol concentration under stress compared with their basal profiles.
This was particularly notable when the maximum morning salivary Cortisol
concentrations were compared. However, the median maximum stressed salivary
Cortisol concentration (18.6 nmol/L) was only slightly higher than the median basal
value (interquartile range 10.8 to 24.9 nmol/L; Figure 6.30). The unwelbwell
maximum salivary Cortisol ratio varied from 0.6 to 3.0 (median value = 1.2). The
median minimum stressed salivary Cortisol concentration was 3.4 nmol/L
(interquartile range 2.0 - 6.9 nmol/L). This was significantly higher than the median
minimum basal values in these patients and higher than the controls (1.4 nmol/L).
Comparing AUC for profiles taken under basal conditions and under stress, the
differences between the basal values and stressed values were variable. The
unwelhwell ratios of area under the curve for salivary Cortisol profiles varied from 0.7
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6.3.5.2 Salivary 17-Hydroxyprogesterone Profiles
There was also a diurnal variation in salivary 17-OHP concentration in the 24 hour
profiles in the study patients. The median maximum and minimum salivary 17-OHP
concentration was similar in girls and boys (Tables 6.6 and 6.7 respectively).
Comparison of basal and stressed concentrations of maximum and minimum
salivary 17-OHP concentrations showed a rise in 17-OHP levels in response to
stress in some but not all of the patients.
In the patients with abnormal salivary Cortisol profiles, the 17-OHP profiles did not
provide any additional information. The profiles in these patients were either normal
or demonstrated low concentrations (particularly in one patient B16).
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6.3.5.3 Salivary Androstenedione Concentration
There was also a diurnal variation in salivary androstenedione concentration in the
24-hour profiles in the study patients. The median maximum and minimum salivary
androstenedione concentration was higher in girls than boys.
Comparison of basal and stressed concentrations of maximum and minimum
salivary androstenedione concentrations showed lower in androstenedione
concentrations in response to stress in the female patients, but not in male patients.
Tables 6.6 and 6.7 show the salivary androstenedione concentrations in the female
and male study patient group.
As with the 17-OHP profiles, the androstenedione profiles did not provide any
additional information regarding the likelihood of being hypoadrenal in the patients
with low salivary Cortisol profiles.
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6.3.5.4 Salivary Cortisol/17-Hydroxyprogesterone Ratios
The ratio of salivary Cortisol to salivary 17-OHP was calculated at the maximum and
minimum salivary Cortisol concentrations. The median value (and interquartile
range) for ratios at maximum basal salivary Cortisol concentration for the study
group, control girls and control boys was 61.30 (41.90 to 79.10), 55.6 (42.6 to 77.0),
and 57.5 (41.7 to 91.4) respectively. The median ratio at maximum salivary Cortisol
concentration for stressed profiles in the study group was 41.0 (interquartile range
22.9 to 86.7). Although this was lower than with the basal levels, there was more of
a spread of results; the interquartile range was 22.90 to 86.70.
The median ratios (and interquartile range) at minimum basal salivary Cortisol
concentrations for the study group, control girls and control boys was 19.0 (9.0 to
31.10), 12.0; interquartile range 9.0 to 21.0). For stressed levels in study patients
the median value was 43.65 (interquartile range 14.10 to 69.30).
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6.3.5.5 Salivary Cortisol/Androstenedione Ratios
The ratio of salivary Cortisol to salivary androstenedione was calculated at the
maximum and minimum salivary Cortisol concentrations. The median value (and
interquartile range) for ratios at maximum basal salivary Cortisol concentration for
the study group, control girls and control boys was 31.0 (18 to 61), 21.6 (9.6 to 45),
and 31.9 (14.6 to 56.6) respectively. The median ratio at maximum salivary Cortisol
concentration for stressed profiles was 44 (interquartile range 34 to 95). The median
value (and interquartile range) for ratios at minimum salivary Cortisol concentrations
for basal levels in the study group, control girls and boys was 15 (10 to 28), 21.6
(9.6 to 45) and 31.9 (14.6 to 56.6) respectively). For stressed levels the median ratio
was 38 (interquartile range 1.0 to 63).
6.3.5.6 Salivary 17-Hydroxyprogesterone/Androstenedione
Ratios
The ratio of salivary 17-OHP to salivary androstenedione was calculated at the
maximum and minimum salivary Cortisol concentrations. The median ratio at
maximum salivary Cortisol concentration was 0.59 (interquartile range 0.28 to 0.97).
(C.f. controls: median; girls = 0.64; boys = 0.55; interquartile range 0.45 to 1.0, and
0.34 to 1.3 respectively). The median ratio at maximum salivary Cortisol
concentration for stressed profiles was 0.91 (interquartile range 0.74 to 1.61).
The median ratio at minimum salivary Cortisol concentrations for the basal values
was 0.97 (interquartile range 0.52 to 1.86) (C.f. controls: median; girls = 1.9, boys =
2.2; interquartile range 0.9 to 2.9, and 1.2 to 2.9 respectively) and for the stressed
levels was 1.02 (interquartile range 0.76 to 1.26).
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6.3.5.7 Salivary Steroid Ratios - correlations in study patients
6.3.5.7.1 Ratios at Maximum Salivary Cortisol
Concentration
There was a significant correlation between salivary cortisol/17-OHP ratios and
salivary cortisol/androstenedione ratios for both basal and stressed values. The
correlation coefficient was 0.450 (p = 0.014) for basal values and 0.804 (p<0.001)
for stressed values. There was no correlation found between any of the other ratios
calculated.
6.3.5.7.2 Ratios at Minimum Salivary Cortisol Concentration
There was a significant negative correlation between basal salivary cortisol/17-OHP
ratios and basal salivary 17-OHP/androstenedione ratios, with a correlation of -
0.363. However, this was at the limit of significance, with a p value of 0.049.
There was a significant correlation between basal salivary cortisol/androstenedione
ratios and basal 17-OHP/androstenedione ratios, with a correlation coefficient of
0.519 (p =0.002).
There was reasonable correlation between stressed salivary cortisol/17-OHP ratios
and stressed salivary cortisol/androstenedione ratios (r =0.704, p =0.023).
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6.4 Capillary blood spot profiles in study patients -
Basal and Stressed
Thirty five study patients provided blood spot profiles, of which twenty four profiles
(69%) were suitable for use. Eleven profiles were unsatisfactory due to insufficient
amounts of blood on the filter paper discs and were excluded. The good quality
profiles showed a diurnal variation and also an increase in steroid levels in response
to stress.
The blood spot profiles could not be directly compared with control data as these
were not available. Comparison of blood spot profiles with salivary profiles showed a
correlation coefficient of 0.763 (p<0.0001) when the results from all patients were
pooled together (Figure 6.31). However, there was considerable variation in the
correlation of blood spot and salivary profiles for each patient, correlation coefficient
varying between 0.656 and 0.997 (e.g. B20 Figure 6.32).
The factor expressing the difference between saliva and capillary blood was
calculated and found to be 11.86.
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6.4.1 Blood Spot Cortisol in Study Patients
From the twenty four satisfactory profiles, the median peak morning Cortisol
concentration was 155 nmol/L (range 89 - 284 nmol/L). The median minimum
Cortisol concentration in these profiles was 42.5 nmol/L (range <20 to 200 nmol/L).
The limit of sensitivity of the assay was 20 nmol/L of whole blood.
Eight patients provided blood spot profiles taken when they were unwell. Of these,
only five were suitable due to poor quality of the samples taken.
The median maximum morning capillary blood spot Cortisol concentration in the
unwell profiles was 212 nmol/L (range 138 to 364 nmol/L). The median minimum
capillary blood spot Cortisol concentration was 62 nmol/L (range <20 to 105 nmol/L).
Thus, there was only a slight difference in these values between the well and unwell
profiles.
The median value for AUC was 2133 for the baseline profiles (range 1199 to 4264),
compared with the unwell profiles in which the median value was 3162 (range 1511
to 7157). This shows that Cortisol release is generally increased in stress, with
increases in peak morning values as well as daytime levels.
The results of the capillary blood spot profiles in the study patients is shown in Table
6.8.
6.4.2 Blood Spot 17-Hydroxyprogesterone in Study Patients
The limit of sensitivity of the 17-OHP assay was 2 nmol/L.
Eighteen baseline profiles were available for 17-OHP measurement in blood spots,
five profiles were performed in study patients when they were unwell.
The median maximum 17-OHP concentration in the well study patient profiles was
8.1 nmol/L (range 3.9 to 30.9 nmol/L). The median minimum value was <2 nmol/L
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(range <2 to 4.2 nmol/L). In the profiles performed in patients when they were
unwell, the median maximum 17-OHP concentration was 5.9 nmol/L (range <2 to 13
nmol/L). The median minimum 17-OHP concentration was <2 nmol/L (range <2 to
2.3 nmol/L). The AUC in the well and unwell profiles was 88.9 (range 39.9 to 503)
and 99 (range 45 to 108) respectively. These data suggest that under stress, the 17-
OHP concentrations actually diminish. (See Table 6.8 for the 17-OHP blood spot
results in the study patients).
6.4.3 Blood Spot Androstenedione in Study Patients
Seventeen baseline blood spot profiles were suitable for interpretation. The limit of
sensitivity of the androstenedione assay was 0.1 nmol/L.
The mean maximum androstenedione concentration in these baseline profiles was
9.6 nmol/L (range 4.3 to 25.2 nmol/L), compared with 8.6 nmol/L in the stressed
profiles (range 2.5 to 11.6 nmol/L). The mean minimum concentration of
androstenedione in blood spots was 3.7 nmol/L (range <0.1 to 9.5 nmol/L). In the
stressed profiles (five in total), the mean minimum androstenedione concentration
was 2.5 nmol/L (range <1 to 4.4 nmol/L).
The AUC for the baseline profiles was 142.2 (range 63.6 to 365). It was not possible
to calculate AUC in the stressed profiles as there was insufficient data available.
The raw data for the androstenedione blood spot results in the study patients is
shown in Table 6.8.
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Female study patients in adrenal late effects study
CAPILLARY BLOOD SPOT
Cortisol 17-OHP Androstenedione
No. Diagnosis 8a.m. 11a.m. 5p.m. 8p.m. 11p.m. 8a.m. 11a.m. 5p.m. 8p.m. 11p.m. 8a.m. 11a.m. 5p.m. 8p.m. 11p.m.
G01 ALL relapse 1000 640 177 997 234 ND ND ND ND ND ND ND ND ND ND
G02 TBI - ALL relapse 116 81 35 34 45 4.4 2.3 <2 <2 <2 6.6 0 0 0 4.4
G03 TBI - ALL relapse 144 66 36 11 9 5 <2 <2 <2 <2 ND 4.4 2.8 3 4.9
G04 Ependymoma 214 328 93 124 152 ND ND ND ND ND ND ND ND ND ND
G05 Germinoma ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
G06 Suprasellar asatrocytoma 130 303 112 131 53 7.6 10.1 2.5 ND <2 ND ND 3.7 8 ND
G07 Low grade astrocytoma 153 66 28 10 ND ND ND ND ND ND ND ND ND ND ND
G08 Optic glioma 290 130 149 70 ND 10.8 <2 <2 <2 ND 5.4 ND 1.8 3.1 ND
G09 Optic glioma 143 60 53 17 137 6.1 ND 2.1 <2 8.9 ND ND ND ND ND
G10 Optic glioma 138 69 57 18 19 5.6 4.3 3.2 2.3 4.2 10.4 8 5.1 3.1 ND
G11 Medulloblastoma 186 136 92 46 32 3.8 <2 4.8 <2 >2 ND ND ND ND ND
G12 Medulloblastoma ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
G13 Medulloblastoma 107 68 97 83 200 6.3 4.3 4.6 2.6 9.8 4.3 3.3 5.4 3.6 7.3
G14 Medulloblastoma 271 403 214 80 71 ND ND ND ND ND ND ND ND ND ND
G15 Medulloblastoma ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Male study patients in adrenal late effects study
CAPILLARY BLOOD SPOT
Cortisol 17-OHP Androstenedione
No. Diagnosis 8a.m. 11p.m. 8a.m. 11p.m. 8a.m. 11p.m.
B01 ALL 176 110 86 76 49 9.3 7.7 <2 <2 <2 8.5 8.6 6.1 4.1 1.8
B02 ALL relapse 139 89 50 67 34 ND ND ND ND ND ND ND ND ND ND
B03 ALL relapse 132 89 114 94 35 <2 <2 >2 >2 <2 7.4 6 ND 3.6 1.7
B04 TBI - ALL relapse 268 61 29 18 - 7.3 1.5 0 1.2 ND 5.6 0 0 2 ND
B05 TBI - ALL relapse 182 86 84 49 38 ND ND ND ND ND ND ND ND ND ND
B06 TBI - ALL relapse 284 157 82 54 21 17.7 5.4 2.4 <0.5 1.5 6.3 4.4 3.9 1.5 0
B07 TBI- ALL relapse 138 76 85 39 30 13.5 2.4 2.7 2.2 <2 13.7 ND ND ND 4
B08 TBI-AML 175 141 70 58 111 30.9 37.2 12 9.2 12.7 25.2 24.4 11.3 5.5 8.5
B09 TBI-AML 125 48 47 35 18 ND ND ND ND ND ND ND ND ND ND
B10 TBI-AMML 275 162 96 90 77 23.5 12.6 14 14.8 10.5 18.4 11.6 13.9 9.5 8.7
B11 TBI - Neuroblastoma 185 44 35 31 23 ND ND ND ND ND ND ND ND ND ND
B12 Lymphoma (B cell NHL) 155 185 163 76 52 7 4.5 2.2 4.5 2.4 12.7 13 9.6 5.3 4.6
B13 Brain stem 89 56 35 19 ND 6.7 2.1 1.9 <2 ND 4.4 3.3 2.9 2.9 ND
B14 Glioma ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
B15 Optic glioma ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
B16 Optic glioma ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
B17 Germ cell 159 90 90 47 47 8.3 3 <2 <2 <2 6 7.5 6 5 2.5
B18 Medulloblastoma 259 82 20 10 30 ND ND ND ND ND ND ND ND ND ND
B19 Medulloblastoma 156 81 81 26 ND 1.1 1.7 0.8 0.5 ND ND 2.1 0 0 ND
B20 Medulloblastoma 163 52 50 16 ND ND ND ND ND ND ND ND ND ND ND
B21 Rhabdomyosarcoma of jaw 150 92 48 47 24 7 <2 <2 <2 <2 6.4 ND ND ND 2.6
(ND = No Data)
Table 6.8. Blood spot steroid profile results in study patients.
6.4.4 Blood Spot Cortisol/17-hydroxyprogesterone Ratios in
Study Patients
The cortisol/17-OHP ratio was calculated for the maximum morning Cortisol
concentration in blood spot samples from the study patients. In 12 samples, the
median ratio was 16.9 (range 1.3 to 48.9). The ratio of cortisol/17-OHP at minimum
Cortisol concentrations in blood spot samples was little different at 16 (range 4.5 to
26.5). Ratios of cortisol/17-OHP throughout the day were very variable, suggesting
no particular pattern for Cortisol and 17-OHP concentrations.
6.4.5 Blood Spot Cortisol/Androstenedione Ratios in Study
Patients
Cortisol/androstenedione ratios were calculated in blood spot samples at maximum
and minimum blood spot Cortisol concentrations.
The median cortisol/androstenedione ratio at maximum Cortisol concentration was
15.1 (n=11; range 0.2 to 47.9). and at minimum Cortisol concentration, 12.2 (n=10;
range 1.8 to 210). Again, the median values were comparable, but the ratios in the
samples taken throughout the day were widely varying, with no particular pattern.
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6.4.6 Blood Spot 17-Hydroxyprogesterone/Androstenedione
Ratios in Study Patients
Ratios for 17-OHP and androstenedione were also calculated in 11 study patients.
At the maximum morning Cortisol concentration, the median ratio was 1.5 (range 0.5
to 66). At minimum Cortisol concentrations, the median ratio was 1.0 (range 0.4 to
15). The mean ratios of these steroid hormones throughout the day were not as
widely varying as with the previous ratios calculated, suggesting a certain degree of
stability in the concentrations of these hormones throughout the day.
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6.5 Low Dose (500ng/1.73m2) Synacthen test in Study
Patients
Forty one study patients were subjected to a low dose synacthen test as part of the
assessment of adrenal function. All tests were performed between 09:00 and 11:00
hours. Patients were fasted from midnight the night before the test. Each patient
was given a dose of 500 ng synacthen/1,73m2 body surface area and samples were
taken as described earlier.
The criteria for a normal test was based on the accepted criteria for a normal
response to the standard synacthen test (a peak Cortisol response to standard dose
of synacthen (250pg) of greater than 500 nmol/L, an incremental rise of greater than
200 nmol/L, and a basal Cortisol of greater than 225 nmol/L).
Nine patients had a basal Cortisol concentration of less than 225 nmol/L (median
basal Cortisol 315.5 nmol/L, range 27 to 1038 nmol/L). However, only 3 patients had
a maximum Cortisol response of less than 500 nmol/L (median 730 nmol/L; range 58
to 1640 nmol/L). (See figure 6.33) Eight patients had an incremental rise of less
than 200 nmol/L (median 369 nmol/L; range 31 to 818 nmol/L. (Figure 6.34) Fifteen
patients had at least one abnormal criteria (summarised in Table 6.9).
There was a significant correlation between basal Cortisol concentration and peak
Cortisol concentration (r = 0.64, p<0.001). There was also a correlation between
peak Cortisol concentration and incremental rise of Cortisol in response to synacthen
(r = 0.64, p<0.001).
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Figure 6.32. Correlation between salivary Cortisol and blood spot Cortisol in one










































6.6 Insulin-hypoglycaemia Results in Study Patients
Of the patients studied, only 6 had an insulin hypoglycaemia test performed during
the period of the study. The remainder of the patients who had undergone an ITT
had the test performed over a year previously.
In total, 55 patients had an ITT performed, either as part of a routine investigation
post transplant or post treatment for brain surgery and radiotherapy, or because of a
clinical suspicion of growth hormone deficiency. None of the patients had an ITT
performed purely to investigate possible adrenocortical insufficiency.
None of the patients who underwent an insulin hypoglycaemia provocation test were
shown to have a subnormal Cortisol response to hypoglycaemia.
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6.7 Urinary Metyrapone Test Results in Study Patients
A urinary metyrapone test was performed in five patients in whom there was a high
index of clinical suspicion of ACTH deficiency.
The test involved the patient collecting urine over 24 hours as an initial baseline
collection, following which oral metyrapone was given in a low dose (500 mg/m2).
Metyrapone is an 11(5-hydroxylase inhibitor, which reduces Cortisol concentration by
blocking its synthesis (see Figure). Steroids (11-deoxy) immediately prior to the
block are increased as a result of increased ACTH drive. Following administration of
metyrapone, two consecutive 24 hour urine collections were performed. By
measuring the ratios of Cortisol urinary metabolites to 11 -deoxycortisol metabolites,
and corticosterone to 11-deoxycorticosterone, ACTH deficiency can be assessed.
(218).
From the five patients tested, two patients had an abnormal metyrapone challenge.
These patients also had symptoms of SAI, which were greatly exacerbated by the
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6.8 Diagnostic Breakdown of Adrenal Status based
on the Results in the Study Patients
6.8.1 Normal
Patients with normal adrenocortical function were classified as those with a salivary
Cortisol profile within the reference range and with a normal response to the short
synacthen test. These patients were also asymptomatic in terms of having no
symptoms or clinical features which could have been attributable to adrenocortical
insufficiency, and, where applicable, a normal Cortisol response to insulin
hypoglycaemia, and normal metyrapone test.
Of the patients in the study, 26 patients were found to have normal function
according to these criteria.
6.8.2 Borderline
Patients with a borderline result from the above tests were those in which one of the
tests performed (either the salivary profiles or the low dose synacthen test) was
abnormal. The low dose Synacthen test gave equivocal results in 13 out of 41
patients in whom the test was performed. In all patients with equivocal low dose
synacthen test results, the salivary steroid profiles were normal.
Eight patients had morning salivary Cortisol concentrations below the 25th quartile
compared with the control population. All of these patients had a normal Cortisol
response either to insulin induced hypoglycaemia or to low dose synacthen. (See
Table 6.12).
6.8.3 Abnormal
Two patients had both an abnormal response to low dose synacthen as well as an
abnormal salivary steroid profile (G05 and B22). In one patient (G05) a urinary
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metyrapone test was performed which was also abnormal, suggesting that
adrenocortical insufficiency was as a result of ACTH deficiency. These results also
supported the clinical suspicion that these patients were adrenocortically insufficient.
Table 6.13 summarises the comparisons of the salivary profiles with the low dose




























































































































































































































Table6.12.showinglresultsoft dypatienw thm x mumor ingsal varC r sol concentrationsbelowth25thQuartile.
Patient Salivary Profiles Low does ACTH test Capillary Profiles
G01 N N N
G02 BN - N
G03 BN N N
G04 N N N
G05 A A -
G06 BN N N
G07 N N N
G08 N N N
G09 N N N
G10 BN - N
G11 N N N
G12 N - -
G13 BN N N
G14 N N N
G15 N - -
B01 BN - -
B02 N - N
B03 N N N
B04 N - N
B05 N N N
B06 N N N
B07 BN N N
B08 N N N
B09 N - N
B10 N N N
B11 N N N
B12 N N N
B13 N N N
B14 N N -
B15 - N -
B16 A A -
B17 N N N
B18 BN N N
B19 N N N
B20 N N N
B21 N N N
N = Normal A = Abnormal BN = Borderline normal
Table 6.13. Summary ofResults in Study
Patients
6.9 Summaries of Cases with Abnormal Profiles
6.9.1 Patient Summary 1: Christopher (B16 )
Date of Birth 18/2/77
Christopher had failed a school eye test one year prior to presentation, and had
been wearing spectacles. At the age of six, two weeks prior to admission he was
noted to have right sided weakness, with a poor grip and a slight limp.
A CT scan showed an unusual, almost cystic lesion in the posterior part of the basal
ganglia on the left, displacing the third ventricle. There was a soft tissue mass in the
posterior part of the cyst, and a central increase in density in the suprasellar region
extending across to behind the right carotid bifurcation.
Ophthalmic examination suggested a right homonymous superior quadrantic field
defect and bilateral optic atrophy.
He was taken to theatre and a jelly-like tumour was found between the left side of
the optic chiasm and the left carotid artery, extending back to involve the
hypothalamic region. Biopsy showed this to be a low-grade astrocytoma (optic
glioma). The cyst was drained and 20 ml of fluid removed.
Post-operatively he had diabetes insipidus, which subsequently settled after a short
course of DDAVP. However, the Dl recurred and he has required DDAVP since.
He was treated with radiotherapy in October 1983 (4500 cGy). An insulin
hypoglycaemia test in November 1983 suggested he was growth hormone deficient,
but was not initially commenced on GH therapy. GH was started in 1986.
He had a recurrence of the tumour cyst in May 1984, and an Ommaya reservoir was
inserted to drain the cyst.
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In 1989, thyroid function tests suggested hypothalamic hypothyroidism and was
commenced on thyroxine replacement.
In February 1990, he was admitted with a history of increasing thirst and polyuria,
feeling generally unwell with tiredness. A synacthen test suggested that he was
Cortisol deficient and was commenced on hydrocortisone replacement.
He was commenced on testosterone replacement in August 1990.
In July 1994, the decision was made to challenge the diagnosis of hypoadrenalism,
and his steroid replacement was cautiously withdrawn over 12 to 14 weeks. A low
dose synacthen test showed no Cortisol response, and a urinary metyrapone test
was abnormal. His salivary steroid profiles showed a flat Cortisol profile, confirming
ACTH deficiency. He was therefore recommenced on hydrocortisone.
He is currently doing very well, although is somewhat obese. He has reached a final
height of 178.6 cm (above 50th centile). He has completed puberty although only has
2-3 ml testes in keeping with gonadotrophin deficiency.
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6.9.2 Patient Summary 2: Mary (G05)
Date of Birth 10/03/80
Diagnosed aged 12 years following a six month history of intermittent headache,
and a right convergent squint. Just prior to admission she developed a history of
increasing lethargy, weight loss, and headaches.
On presentation, she had bilateral papilledema. A CT scan showed an enhancing
suprasellar mass.
A biopsy of the mass confirmed a germinoma. Bilateral VP shunts were inserted and
she was treated with chemotherapy (combination of bleomycin, etoposide, and
cisplatin in six courses). She was then given radiotherapy, 4000 cGy in 23 fractions
over 33 days.
Post surgery there was evidence of secondary hypothyroidism (Total T4 49nmol/l,
TSH 0.22 mU/l) and diabetes insipidus, and was commenced on thyroxine and
DDAVP.
A repeat CT scan showed resolution of the tumour mass.
Following radiotherapy she had profound weight loss and required a short spell in
hospital for nasogastric feeds.
Anterior pituitary function tests in August 1993 showed complete GH deficiency,
gonadotrophin deficiency and TSH deficiency. The Cortisol response was normal,
with a peak of 1472 nmol/L.
She was commenced on GH therapy in addition to thyroxine and DDAVP.
Over the following six months she continued to have problems with weight loss and
vomiting. In March 1994, salivary steroid profiles showed a flat Cortisol profile, which
was confirmed by a low dose synacthen test and urinary metyrapone test.
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Once she was commenced on hydrocortisone replacement, she made a dramatic
improvement, with weight gain, and improved appetite.
She was commenced on oestrogen replacement aged she was diagnosed as having
partial gonadotrophin deficiency and was commenced on oestrogen replacement
therapy.
To date, her main problems are of increasing weight gain, but this is partly due to
overenthusiastic use of hydrocortisone during trivial illness.
At 17.5 years of age she developed classical symptoms of adult GH deficiency with
extreme tiredness, lethargy, and reduced exercise tolerance. She was commenced
on GH therapy. Her response to treatment was dramatic with resolution of her
symptoms.
Repeat CT scans have shown no evidence of recurrence.
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6.9.3 Patient Summary 3: Gareth (B18)
Date of Birth 30/11/78
Presented at 11 years of age with a five weeks history of persistent headache,
nausea and dizziness. Clinically there was a left sixth nerve palsy, but no
papilledema at presentation.
A CAT scan showed a medulloblastoma, and a sub-total surgical removal was
performed (95% removal) together with pre-operative shunting, followed by
radiotherapy. He received 3500 cGy in 21 fractions over 29 days to the whole brain
and spinal axis, and 1980 cGy in 11 fractions over 17 days to the tumour site, along
with dexamethasone.
He did very well following his radiotherapy.
Aged 12 years, evaluation of his anterior pituitary function was performed. This
showed growth hormone deficiency, but no other endocrine deficit. He was
commenced on growth hormone therapy, with good effect.
At the age of 14 he began to develop symptoms that may have suggested ACTH
deficiency, with tiredness, lethargy, lacking in energy, and prolonged recovery
following viral illness. A low dose synacthen test showed a normal Cortisol response
with a peak Cortisol concentration of 650 nmol/L. However, salivary steroid profiles
showed loss of diurnal rhythm, with morning Cortisol concentrations at the lower limit
of normal. He was commenced on hydrocortisone replacement with significant
positive clinical response with long lasting improvement in his symptoms. He
continued to do well, with a good quality of life.
At the age of 17.5 years, he had reached a final height of 170.2 cm, and had
completed secondary sexual development.
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At the age of 20 years, he continues to do well with no problems to date. He
continues on hydrocortisone replacement therapy with no adverse effects. He is now
regularly reviewed by the adult oncologists and endocrinologists.
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6.9.4 Patient Summary 4: Kelly Ann (G10)
Date of Birth 5/2/1980
Presented at the age of 3 years with a divergent squint in the right eye. Surgery to
correct the squint was performed in 1983 aged 13 years, but the squint gradually
recurred with poor vision in the right eye. Initially, fundoscopic examination was
normal. Subsequently, in early 1984, she was noted to have right optic atrophy. A
skull film showed an enlarged pituitary fossa with erosion of the anterior clinoid
processes and thinning of the dorsum sellae, with widening of the right optic canal.
A CT scan showed widening of the right optic nerve infra-orbitally, with evidence of a
suprasellar mass extending posteriorly and to the right.
At craniotomy, the optic nerves and chiasm were found to be involved in a large
mass of solid tumour. There was no hypothalamo-pituitary involvement. Biopsy of
the lesion confirmed an optic nerve glioma.
She was treated with radiotherapy in April 1984, with a total dose of 5000cGy in 30
fractions over 44 days, using a three field plan and 4 MeV x-rays. The treatment was
effective in shrinking the tumour. She was subsequently diagnosed as having
neurofibromatosis with multiple cafe au lait spots.
Anterior pituitary function testing was performed in 1986, aged 6 years, which
demonstrated growth hormone deficiency. She was started on growth hormone
therapy with good results.
Aged 8 years, she showed pubertal progression, with biochemical and bone age
evidence of precocious puberty, and was commenced on Buserelin (an LHRH
analogue). She showed little pubertal progression on this treatment. In 1990, aged
10 years, a TRH test also showed evidence of primary hypothyroidism and was
commenced on thyroxine replacement.
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In 1993, aged 13 years, Kelly Ann developed symptoms of tiredness, especially
early morning, and difficulty in shaking off trivial infection.
A salivary steroid profile showed subnormal Cortisol concentrations, suggestive of
hypoadrenalism, and she was commenced on hydrocortisone replacement. She had
a good clinical response to replacement therapy that has continued.
At the age of 16 years, she had reached a height of 156.8 cm, was pubertal




The accurate diagnosis of secondary adrenocortical insufficiency is a great
challenge, particularly in the childhood population of cancer survivors. The diagnosis
is difficult to make with confidence, as standard tests of adrenal function can give
misleading results (Borst, Michenfelder, & O'Brian 1982). There continues to be a
lively debate as to which test is the best and most accurate, (Clayton 1997) with
convincing arguments for whichever test is favoured. The debate also continues
regarding the accuracy of tests of adrenal reserve, and their significance in
everyday life in terms of the individual's ability to cope under physiologically stressful
events. It is arguable that the assessment of adrenal steroids in normal
physiological conditions is at least as accurate in determining adrenal function as
dynamic tests. Adrenal steroid status is a dynamic process and the value of non-
physiological stimuli to assess adrenal status remains controversial.
The use of saliva in the assessment of hypothalamo-pituitary-adrenal function is
attractive; it is non-invasive, stress-free and requires little if any supervision.
One aim of this study was to develop and evaluate sensitive assays of adrenal
steroids in saliva to allow measurement of salivary steroid day profiles in patients at
risk of developing adrenocortical. With advances in RIA techniques and with the
development of specific antibodies, accurate measurement of these steroids in
saliva was possible. Adrenal steroid immunoassays have been developed which are
extremely sensitive, even using small sample volumes. The salivary Cortisol assay
developed as part of this study was developed specifically for use in screening
children at risk of developing SAI. As a consequence, there were two essential
requirements:
205
1. The assay had to be as sensitive as possible in order to be able to detect very
low concentrations of Cortisol in saliva
2. The assay could be performed with very small sample volumes (50pl), because
of the potential difficulties in obtaining samples of saliva in children.
Read, Riad-Fahmy, Walker, et al, at the Tenovus Institute in Cardiff (Riad-Fahmy,
Read, Walker, & Griffiths 1982) performed much of the foundational work on salivary
steroid profiles. There is now a great deal of research evidence on the use of saliva
and the behaviour of a variety of steroid hormones in saliva is now accurately
described. It was on this foundation that the salivary steroid assays for this study
were developed.
7.1 Salivary steroid assay development
The assays developed in this study were found to be robust and gave reliable and
reproducible results. The assays developed were also relatively simple and quick to
perform. Unfortunately, there is little comparative data with which to compare the
results of these assays with other studies.
7.1.1 Salivary Cortisol Assay
A simple non-extraction assay using uncomplicated and well-established routine
laboratory techniques was developed. The use of encapsulated antibody made the
assay more robust as the antibody-ligand complex was more stable and separation
of antibody-ligand complex from ligand was simple to perform (Wallace 1992). The
use of iodinated label was also advantageous because it had a high specific activity,
and was easy and relatively cheap to detect, despite its relatively short half-life
(Gilby et al 1973; Lindberg & Edqvist 1974). The assay was technically easy to
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perform, allowed easy processing of large numbers of samples and produced
reproducible results in a relatively short time.
An assay sensitivity of 0.9 nmol/L suggested this was a highly sensitive assay.
Moreover, it had acceptable intra- and interassay coefficients of variation, low cross-
reactivity, and hence high specificity.
7.1.2 Salivary 17-Hydroxyprogesterone and androstenedione
assays
The 17-OHP and androstenedione assays were adapted from previously developed
assays in the regional endocrine laboratory in Glasgow.
The 17-OHP assay developed in this study similarly made use of encapsulated
antibody; the method was very similar to the salivary Cortisol assay. The sensitivity
and precision of the assay were adequate to the task.
The androstenedione assay was more laborious and time consuming, involving
solvent extraction prior to radioimmunoassay. The solvent extraction process was
necessary because of the presence in patients' samples of high concentrations of
cross-reacting polar conjugates of steroids (Goodall & James 1981). The presence
of steroid binding proteins as a possible source of interference was not relevant in
this case, as only very small amounts of these are present in saliva and so are not
significant. The principal binding protein appears to be SHBG, but is present in
saliva in very low concentrations (Selby, Lobb, & Jeffcoate 1988).
The assay sensitivity was again excellent (0.35nmol/L).
7.1.3 Capillary Blood Spot Steroid Assays
Apart from the blood spot Cortisol assay, the capillary blood spot assays for 17-OHP
and androstenedione were developed in-house. Details of their development have
been published elsewhere (Chearskull 1985; Santiago et al 1996).
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7.1.4 Capillary Blood Spot Cortisol Assay
The main problem with measuring Cortisol in blood spots was in overcoming the
effects of protein binding that affected antibody-ligand binding. Initial problems with
the blood spot Cortisol assay were resolved once incubation times were greatly
increased and the assay buffer was changed to citrate/phosphate (pH 4.0). This was
found to be superior to ANS as it did not interfere with antibody binding but was
effective enough to inhibit protein binding, giving optimal assay sensitivity. The
assay had a sensitivity of 20nmol/L whole blood (equivalent to 40nmol/L serum) and
a CV of <10% throughout the working range.
It was unfortunate that control data could not be obtained using capillary blood spot
samples as this was not approved by the local ethics committee.
However, valuable information was gained with the study patient samples that could
pave the way for development of this aspect of monitoring in the future.
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7.2 Control Population Results
The results of the salivary profiles from the control population demonstrated the
feasibility of the assay and collecting domiciliary salivary samples in children.
Although there was no way of assessing whether the instructions were adhered to,
the fact that only 12.5% (21 out of 168 profiles) of the profiles could not be used was
probably a reflection on the simplicity of the technique of saliva collection. These
profiles were excluded from the study because they were of poor sample quality or
low sample volume. All of the remaining profiles showed a diurnal variation of all
three steroid hormones measured. This suggested that the use of a simple method
of obtaining a steroid profile was possible in a home setting. Arguably, obtaining
steroid profiles in a relatively stress-free environment ensures that the profile is an
accurate assessment of physiological adrenocortical function.
It is unfortunate that none of the control subjects provided samples of saliva when
they were unwell.
7.2.1 Salivary Cortisol Profiles
The salivary Cortisol profiles exhibited a diurnal pattern with peak salivary Cortisol
concentrations in the morning. There was acceptable intra-individual variability in
the morning samples; a maximal value was obtained in at least one of the two
morning samples, but many of the profiles had peak concentrations in both morning
samples.
When comparing the consecutive morning samples in the 139 controls that provided
two samples, there is a similar spread of results in both groups. There is however a
relatively low correlation coefficient, suggesting perhaps more variability than might
be expected. It has been suggested that a peak Cortisol concentration may be
missed if a specific time of the day is chosen (Katz & Shannon 1964). The reason
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that some of the profiles did not show peak concentrations in both morning samples
might be that the samples were not taken at the same time each day in each
individual. The controls were asked to take the morning sample at 8 a.m. because it
was felt that this was the most convenient time, and because this was most likely to
be around the time of wakening. Peak Cortisol concentrations have been shown to
be related more to the time of wakening; Cortisol concentrations begin to fall within
30 minutes of wakening (Lindholm et al 1978). The results would therefore suggest
that several morning samples should be obtained to ensure that maximal salivary
Cortisol concentrations are obtained.
There was no correlation with salivary Cortisol and age and body size, as has been
noted in other studies looking at both serum and salivary Cortisol concentrations.
The fact that the salivary Cortisol reference range in the control children studied is
similar to adult reference ranges in other studies also suggests that age does not
affect Cortisol concentrations. The values obtained in the control population compare
favourably with control values in other studies (see Table 7.1). There was a wide
range of Cortisol concentrations in the controls, particularly in the first morning
samples, ranging from 4.6nmol/L to 35.9nmol/L. The salivary Cortisol concentration
in the morning sample may also reflect what the child was doing at that time of day,
as well as indicating true physiological basal concentrations. In some of the children,
the 8a.m sample may not have been taken at the time of that particular child's peak
Cortisol production and hence may not demonstrate the child's maximal Cortisol
concentration if the time for maximal Cortisol production was missed. This would
then result in a misleading result and lead to an erroneous suspicion of SAI in the
study patients. The samples were also not necessarily taken when the child was at
rest. For example, if the child had run up and down the stairs prior to obtaining a
sample of saliva, then this may result in an inadvertently high salivary Cortisol
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concentration. This would not be a problem when looking for evidence of
adrenocortical insufficiency, but would be a problem when determining Cortisol
excess.
Thus when identifying SAI only the first morning sample is informative. This is
further suggested by the finding that calculation of AUC gave no further information.
If one hypothesised that in hypoadrenalism, total Cortisol production is reduced, then
calculation of the area under the curve might provide an estimate the total daytime
Cortisol release. Calculation of the area under the curve for salivary Cortisol
unfortunately did not provide any additional information regarding adrenal function.
Calculating the area under the curve was simply an alternative method for obtaining
the average concentration of salivary Cortisol throughout the day, with the effect of
diminishing the importance of the morning Cortisol concentration.
The lack of a significant sex difference for salivary Cortisol concentration was also in
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7.2.2 Salivary 17-Hydroxyprogesterone Profiles
A diurnal pattern of 17-OHP concentration was also found in the salivary steroid
profiles. In general, the daytime 17-OHP concentrations were very low, with a large
proportion of the daytime samples having salivary 17-OHP concentrations below the
limit of sensitivity of the assay. Of the daytime salivary 17-OHP concentrations, 107
out of 141 samples (76%) were below the limits of sensitivity of the assay.
The sex difference found with the maximum and minimum salivary 17-OHP ratios
was small but statistically significant. Salivary 17-OHP concentrations were slightly
higher in adolescence in girls than in boys. The correlation between age and 17-
OHP in girls may be due to a variety of reasons. 17-OHP is produced in the ovary,
testis and the adrenal gland. In older children the proportion of 17-OHP produced by
the gonads becomes more significant as children progress through puberty.
Increased 17-OHP concentrations are also found in adrenarche (Tanner & Gupta
1968).
Maximum 17-OHP was not shown to increase with age in boys, probably because
sex steroid concentrations in boys rise predominantly in the second half of puberty,
while our sample population of boys were either prepubertal or in early puberty.
The fact that minimum salivary 17-OHP concentrations also rise in relation to age
and body surface area, might also be further evidence to suggest that the gonadal
component of salivary 17-OHP production becomes more significant with age and
with the onset of puberty. One must presume that a significantly larger proportion of
the older girls in the control group were in established or late puberty. It is known
from previous studies in children that activation of the adrenal cortex occurring in
adrenarche and early puberty occurs later in boys than in girls (Tanner & Gupta
1968). If salivary profiles were obtained in boys up to the age of approximately 17
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years, then perhaps we would see a correlation in salivary 17-OHP concentrations
with age and body size. This would be an area for future study.
7.2.3 Salivary Androstenedione Profiles
The androstenedione concentrations in the salivary profiles followed a similar
diurnal pattern to that obtained for salivary Cortisol (See Table 4.5).
The salivary androstenedione concentrations were also found to correlate positively
with age in girls at both maximum and minimum salivary androstenedione
concentrations. Area under the curve also correlated positively with age. As with
salivary 17-OHP profiles in this study, there was no such correlation found with the
male control group, presumably for the same reasons as with salivary 17-OHP.
The sex difference noted for both maximum salivary androstenedione
concentrations and also AUC has been described previously with serum
concentrations but not in saliva (Apter et al 1979). Salivary androstenedione
concentrations were higher in all age groups tested.
Little work has been published with regard to salivary androstenedione
concentrations in normal children. In the study by Young (Young, Walker, Riad-
Fahmy, & Hughes 1988b), the increase in salivary androstenedione with age is
more noticeable than with 17-OHP concentration. Presumably with advancing age,
either the gonadal production of androstenedione assumes greater importance, or
there is predominantly greater androstenedione production in the adrenal gland in
males than in females. However, adrenal androgens have been shown to rise during
childhood, at least in part due to adrenal maturation (Tanner & Gupta 1968).
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7.2.4 Salivary Steroid Hormone Ratios
The reason for calculating salivary steroid ratios was to determine whether changes
would occur in the ratios of adrenal steroids with diminishing ACTH drive, and if this
would be helpful in the diagnosis of SAI.
The difference in ratios at maximum and minimum salivary Cortisol concentrations is
presumably a consequence of a greater change in salivary Cortisol through the day
than salivary 17-OHP; salivary Cortisol concentrations have a proportionately greater
fall than salivary 17-OHP. There was no sex difference for ratios at both maximum
and minimum salivary Cortisol concentrations. The spread of results was greater in
boys than girls.
The fall in cortisol/17-OHP ratios with age in boys is difficult to explain, as no
correlation was found for the Cortisol and 17-OHP concentrations. However, the
correlation is just at the level of significance and this relationship may be
coincidental.
There is a slight fall in salivary cortisol/androstenedione ratios from maximum to
minimum salivary Cortisol concentrations. This again may be explained because of a
greater fall in salivary Cortisol than salivary androstenedione.
There is no sex difference found with these ratios, presumably because the relative
ratios between the two steroids are the same.
The ratios at maximum salivary Cortisol concentrations are lower than at minimum
concentrations, probably as a result of a greater fall in salivary 17-OHP than
androstenedione. Once more there is no sex difference for the ratios at maximum
and minimum salivary Cortisol concentrations.
215
7.3 Study Group Results
The steroid profiles performed in the study group were performed under similar
instructions as with the control group, and at the same times throughout the day. In
this way, a direct comparison could be made between the study patients and
controls. Both saliva and capillary blood samples were taken in 31 study patients
(13 girls), enabling the relationship between saliva and capillary blood spot profiles
to be studied. In addition, some of the study patients provided profiles when they
were unwell as well as when they were well. Although these profiles could not be
directly compared with the control group (as none of the control group provided
unwell profiles), the well and unwell profiles for each patient could be compared.
7.3.1 Salivary Cortisol profiles
The salivary Cortisol profiles in the study patients were comparable with the control
group except in two patients, who did not demonstrate a diurnal pattern of variation
in Cortisol concentration. These patients had salivary Cortisol concentrations at the
limit of sensitivity of the salivary Cortisol assay. One of the patients (G05) had
symptoms suggestive of hypoadrenalism. In a low dose Synacthen test the patient
failed to demonstrate a Cortisol response to ACTH, and the patient also failed to
show increased 11-hydroxysteroid concentrations with an oral metyrapone
challenge. In the other patient (B22) there was an initial diagnosis of SAI made on
clinical grounds. However, this diagnosis was in doubt, and with no good objective
evidence of hypoadrenalism, he was tentatively weaned off steroid replacement
therapy over eight weeks, following which salivary profiles were performed over two
days. These profiles failed to show any measurable Cortisol in saliva. A low dose
Synacthen test also failed to demonstrate a Cortisol response to ACTH, and he had
an absent response to metyrapone in a three day urinary metyrapone test.
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Two other patients with symptoms suggestive of hypoadrenalism, had profiles that
were at the lower end of the normal range, although were not frankly abnormal. In
one of these patients (B18), a low dose Synacthen test was normal. He was
commenced on hydrocortisone replacement following which his symptoms
improved. He has continued to remain symptomatically well. The other patient (G10)
was found to have a normal Synacthen test and a salivary profile at the lower end of
the normal range. This patient was commenced on hydrocortisone but this was later
discontinued. The symptoms subsequently recurred and hydrocortisone was
recommenced with good effect.
In patients who are developing SAI there may be subtle changes in their salivary
Cortisol profiles, and their salivary Cortisol concentrations may be at the lower end of
the normal range. However, in the patients in this sub group (see Table 6.12), other
tests of adrenal function failed to show any evidence of hypoadrenalism. It is
important that this group of patients are followed to determine whether they may
develop SAI in time.
As expected, comparison of the well and unwell profiles for each of the remainder of
the patients in general showed an increase in salivary Cortisol concentrations in
response to stress, which was usually an acute viral illness. However, the difference
in salivary Cortisol concentrations was variable. This is most likely to be because of
the subjective nature of the illness and the patient's own interpretation of being
unwell. Although the patients were given a strict definition of what was to be
accepted as being unwell, the final interpretation of the definition was dependent on
the patient and his/her family's perceptions. It could not be concluded from the
current study whether any of the study patients had abnormal steroid profiles in
response to stress. In those patients with significantly raised salivary Cortisol
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concentrations in response to stress, the salivary Cortisol concentrations were raised
throughout the day, and not just in the morning samples.
In patients at risk of developing SAI, perhaps when looking for subtle changes in
adrenal function there may be an initial loss in the daytime increase in the Cortisol
response to stress. This would need significantly more data to show whether this
was indeed the case, and also more control data in stress situations.
7.3.2 Salivary 17-Hydroxyprogesterone and Androstenedione
Profiles
The salivary 17-OHP profiles were also comparable with those of the control group.
The concentrations in the patients with flat salivary Cortisol profiles were also
comparable, with no reduction in 17-OHP concentrations in the morning. This is
presumably because the salivary 17-OHP concentrations are already low and so it
would be very difficult to detect even lower concentrations.
When the two groups were compared (excluding the patients with definitely
abnormal profiles), there was no statistically significant difference between them.
However, the median maximum and minimum salivary 17-OHP concentrations were
slightly higher in the male study group than in the male control group, but slightly
lower in female study group than in the female control group.
In the patients with abnormally low salivary Cortisol profiles, the 17-OHP profiles
were not of any additional help. In fact, they were somewhat misleading, as the 17-
OHP concentrations were generally within the reference range. This again supports
the hypothesis that the 17-OHP levels are simply reflecting gonadal function rather
than adrenocortical steroid release.
The salivary cortisol/17-OHP ratios for maximum and minimum salivary Cortisol
concentrations followed the same pattern as with the control group.
However, interestingly, the stressed ratios were higher than the basal
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concentrations at maximum salivary Cortisol concentrations, but the same when the
basal and stressed ratios at minimum salivary Cortisol were compared. This
suggests that there is a significantly greater relative fall in salivary 17-OHP
concentration under stress compared with the increase in Cortisol concentration
under stress, implying that the Cortisol synthetic pathway is driven towards Cortisol
synthesis in stressful situations. Thus, it is possible that an increase in ACTH drive
results in an acceleration of the adrenal steroid biosynthetic pathway, such that
there is preferential Cortisol (and possibly mineralocorticoid) production at the
expense of androgenic steroid production, resulting in relatively lower
concentrations of the steroid precursors such as 17-OHP.
The ratios of salivary Cortisol and androstenedione followed a similar pattern to the
salivary cortisol/17-OHP ratios. The ratios were higher under stress compared with
basal conditions at maximum salivary Cortisol concentration. However, the ratios at
minimum salivary Cortisol concentration were higher under stress than under basal
conditions. This suggests that Cortisol is preferentially synthesised at the expense of
androstenedione in times of stress. Thus, the steroid pathway may again be diverted
along the Cortisol biosynthetic pathway, with relatively less androgens being
produced. A further study is required to confirm this.
The salivary 17-OHP/Androstenedione ratios increase with stress at maximum
salivary Cortisol concentrations but not at minimum concentrations. The change in
ratios is not as striking as with the ratios involving Cortisol. However, there is a
definite rise in 17-OHP/androstenedione ratio at maximum salivary Cortisol
concentrations. This suggests that there is a relative increase in 17-OHP
concentration compared with androstenedione concentration resulting from either a
proportional increase in 17-OHP or a decrease in androstenedione. If this is the
case, then it may be that Cortisol production is increased at the expense of
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androgen production, as well as increasing Cortisol production by utilising 17-OHP in
the Cortisol biosynthetic pathway. It might be that this situation also occurs in
conditions of falling ACTH concentrations, when enzyme sensitivity to ACTH may
change in favour of Cortisol synthesis. This is speculative, as unfortunately, there
were insufficient numbers of patients with hypoadrenalism to confirm this. Further
studies may provide further information as to whether this hypothesis is correct.
7.3.3 Capillary Blood Spot Steroid Profiles
The capillary blood spot profiles performed in the study patients similarly followed a
diurnal pattern, with close correlation with the salivary profiles. This correlation was
quite variable in the study patients, with some profiles showing poor correlation with
the salivary profiles taken at the same time. This might reflect the inadequacy of
obtaining satisfactory blood spot samples. In a significant number of study patients,
the quality of blood spot samples obtained was poor. It is also possible that some of
the blood spot samples were not taken at the same time as the saliva samples and
so a correlation could not be obtained. However, in reliable patients in whom it was
felt that the instructions regarding taking samples was closely followed, there was
excellent correlation between saliva and capillary profiles, with some patients
exhibiting a correlation coefficient between saliva and capillary blood spot profiles of
0.9 or greater.
As there were no capillary blood spot samples in the control group, no comparison
with normal children could be made.
7.3.4 Low dose Synacthen Test
The low dose Synacthen test has been introduced over the past ten years. It is
relatively straightforward to perform, and it has also been shown to give results
comparable to the standard short synacthen test when compared with healthy
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adults. It has also been shown to give results equivalent to a physiological response
to ACTH in healthy adult subjects (Crowley, Hindmarsh, Holownia, Honour, & Brook
1991).
In this study, the results of the low dose synacthen test confirmed the presence of
hypoadrenalism in the two patients with abnormal profiles.
The results showed that using all the criteria for the standard 250pg synacthen test
resulted in a false positive rate of 29%. However, only the patients with abnormal
salivary profiles failed to reach a peak serum Cortisol concentration of at least 500
nmol/L. If this criterion is used in diagnosing SAI, then the two patients with
borderline low profiles would not be diagnosed if only the low dose synacthen test is
used, as these patients had a normal response to synacthen. It is significant to note
that an abnormal response to low dose Synacthen was not always associated with
an abnormally low salivary Cortisol concentration. Conversely, an abnormal salivary
Cortisol profile was always associated with an abnormal response to low dose
Synacthen.
The low dose Synacthen test has been heralded as a sensitive method of assessing
physiological adrenocortical reserve, and as such is felt to be a useful test in
diagnosing adrenocortical insufficiency, including SAI. However, in this study, we
have shown that the results of the low dose Synacthen test may be misleading, and
may result in an over diagnosis of SAI, and result in inappropriate treatment of these
patients with hydrocortisone replacement. Previous studies have also highlighted
problems in the interpretation of the results of tests of adrenal reserve and have also
shown discrepancies between the different tests performed (Borst, Michenfelder, &
O'Brian 1982; Cunningham, Moore, & McKenna 1983; Tsatsoulis, Shalet, Harrison,
Ratcliffe, Beardwell, & Robinson 1988).
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The results of the low dose Synacthen test in this group of patients illustrate the
problems associated with using the synacthen test in diagnosing hypoadrenalism
secondary to ACTH or CRH deficiency, and it is therefore not recommended as a
method to be used alone in the diagnosis of SAI.
7.3.5 Single dose oral three day urinary metyrapone test
A three day urinary metyrapone test was performed in five patients in this study.
This was primarily to assess the efficacy of the test, and the practicalities of
performing the test as a procedure that could be performed at home. It was
performed in two patients (M.W; C.M.) who had an abnormal salivary Cortisol profile
and an abnormal low dose Synacthen test.
The administration of even a single relatively small dose of metyrapone in these
patients resulted in an accentuation of symptoms that were more attributable to
hypocortisolism. Although the results of the metyrapone test were abnormal, the
results were relatively subtle. It is questionable as to whether it is appropriate to
subject patients to metyrapone who are suspected of being Cortisol deficient, and so
exposing them to even greater risks of adrenal crisis in a situation where there may
not be immediate assistance.
As a screening test in its own right, it probably does not have anything additional to
offer over the salivary profiles with regard to ability to screen for SAI.
7.3.6 Insulin hypoglycaemia provocation
None of the study group had an ITT performed if the diagnosis of SAI was
suspected. The majority of patients in the study had had an ITT up to a year
previously, and further exposure to unnecessary risk of the procedure was felt to be
unethical and inappropriate. Other studies have suggested that patients with SAI
may have an abnormal Cortisol response to hypoglycaemia, but a normal Synacthen
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response (Borst, Michenfelder, & O'Brian 1982; Cunningham, Moore, & McKenna
1983) and vice versa (Tsatsoulis, Shalet, Harrison, Ratcliffe, Beardwell, & Robinson
1988). This begs the question as to which of the tests of adrenal reserve is actually
demonstrating an abnormality, and which is showing an inappropriately high false
positive rate.
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8 Conclusions and Recommendations
This study highlights the difficulties in diagnosing SAI in this particularly complicated
group of patients. The need for continuing screening for SAI is paramount, as these
patients are at risk of developing SAI following treatment. The patients are also at
potential risk of having many years of ill health and morbidity as a result of SAI
which may not be detected, and which may be partial and yet which can still
produce vague symptoms of ill health.
The use of salivary profiles is a simple, sensitive procedure for assessing adrenal
function in a physiological way and can be used to monitor adrenal function in these
children. This avoids repeated provocation tests to assess adrenal function. Saliva
collection is generally well tolerated by the children studied as well as by the control
group. As a group, the survivors of childhood cancer will require life-long
surveillance of their endocrine status. This is true not only of adrenal function, but
also of thyroid function. The use of saliva in monitoring adrenal function is a safe,
non-invasive method that can be used as often as is necessary.
This study has shown that the results of the peak morning salivary Cortisol
concentrations are probably as informative as day profiles. We therefore
recommend that morning and evening samples should be collected on three
consecutive days. If the results are subnormal (the peak salivary Cortisol
concentration is less than 6.5nmol/L), a low dose synacthen test should be
performed. If the results of the low dose Synacthen test are equivocal or normal,
then the salivary samples should be repeated, or if there are symptoms highly
suggestive of hypoadrenalism, then one could tentatively commence steroid
replacement and critically assess the response to treatment.
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In patients in whom the salivary profile remains consistently at the lower end of the
normal range (below the 25th quartile of the reference range, i.e. a Cortisol
concentration of less than 10.3 nmol/L), the salivary profile should be repeated. If
the repeat profile shows a persistently low Cortisol in the morning (less than 10.3
nmol/L), low dose synacthen test should be performed in order to ascertain their
degree of adrenal reserve. The question is whether these patients who have low
normal salivary Cortisol profiles but a subnormal response to low dose synacthen
should be given hydrocortisone in times of physiological stress.
The salivary profiles should be repeated once a year if the patient remains well, and
they should be performed more frequently if there are developing symptoms
suggestive of hypoadrenalism.
Figure 8.1 is an algorithm demonstrating the management of children at risk or
suspected of having SAI.
The use of an ITT in the assessment of adrenal reserve alone is not justified unless
the growth axis is also to be assessed.
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Figure 8.1. Algorithm for the Management of Children at risk of
Secondary Adrenocortical Insufficiency
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10 Appendix
Appendix 1. Consent form for control group.
I do / do not* give permission to allow my child
, to provide samples of saliva only for a
study being undertaken by Dr. John Schulga at the Royal Hospital for Sick
Children, Yorkhill, for the measurement of steroid hormones.
I understand the nature of the study as explained to me in the information
sheet provided by the research team at the hospital.
I also understand that the results of the tests will be strictly confidential.
I confirm that my child 1.1s not currently taking steroids in any form.
2. Has not been taking steroids in the past 2
weeks.
3. Does not have a long-term illness as far as I
am aware.
Dr. John Schulga
Research Fellow in Paediatric Endocrinology.




Appendix 2. Information Sheet for Saliva Study.
INFORMATION SHEET FOR SALIVA STUDY
I am currently developing a test for measuring steroid hormones in saliva.
This will replace blood tests, which can be painful and unpleasant, and at
times difficult to perform in small children.
In particular I am measuring a steroid hormone in saliva called Cortisol. This
is produced naturally in the body, and is essential when you are unwell, for
example, in helping to fight infections.
The reason for developing the test is so that we can diagnose children
lacking these hormones. A particular group of children at risk of becoming
deficient in Cortisol are those who have been treated for various childhood
cancers, including leukaemia.
With this saliva test, we will be able to let the children take samples at home,
instead of having a blood test in hospital.
However, we need samples of saliva from normal healthy children, so that we
know what the normal levels of these steroid hormones should be.
I would be most grateful if you would consider allowing your child to provide
samples of saliva. There would be NO blood tests involved. I must also
stress that the results would be strictly confidential.
Your child would be asked to provide 5 or 6 samples of saliva per day for 1
or 2 days; one day when they are well, and if possible, one day when they
are unwell with a cough or cold and a temperature. This is done by simply
spitting into a plastic tube.
Your child will also be weighed, and their height measured so that the results
of the tests can be accurately compared.
The samples need to be frozen as soon as possible after they have been
taken, so if you do not have ready access to a freezer, I am afraid you will
not be able to do the test.
Also, if your child is currently taking steroids, for example, by inhaler for
asthma (such as becotide, or pulmicort), then they will also be unable to take
part, as these may interfere with the test.
If, after careful consideration, you feel that you can allow your child to take
part, you will receive further information regarding the test in the near future.
Approval for the study has been granted by the Department of Education at
both regional and divisional levels.
Please complete the attached form, which is a requirement of the Hospital
ethics committee, and return it to the class teacher at school. Please note
that your signature needs to be witnessed. This can be done by anyone,
including your husband or wife.
Thank you for taking time to read this letter.
Yours faithfully,
John Schulga
Research fellow in Paediatric Endocrinology.
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Appendix 3. Collecting Saliva Samples.
Thank you for agreeing to provide samples of saliva for this study.
The bottles are labelled 1 to 6 and also have a time on them. Please keep to the
times as closely as possible. The labels are as follows:
1 - 8a.m. (08.00)
2 - 11a.m. (11.00)
3 - 5p.m. (17.00)
4 - 8p.m. (20.00)
5 - 11p.m. (23.00)
6 - 8a.m. (08.00 the following day).
The labels on each tube looks like this:




Sample type (either well or unwell)
Date samples taken.
Please write the date on each tube
Time of sample
Please note that there are two 8a.m. samples.
If possible, please collect the 11 p.m. sample, but if you feel that this is too late for
your child, then ignore it.
Please collect the 6 samples over 24 hours, starting at 8a.m and
finishing at 8a.m the next day.
There are two sets of bottles labelled WELL and UNWELL. Please collect samples
in the WELL bottles when your child is his/her normal self.
It will be helpful if the samples were taken during the weekend beginning Saturday
23rd, April,1994, and brought to school on Monday morning, 25th, April.
Please remember to FREEZE the samples as soon as possible after they are taken.
IF POSSIBLE collect samples in the UNWELL bottles if your child has any of the
following:
1. A temperature
2. A cough or cold that keeps them off school.
If your child is not unwell by the 20th, June, 1994, then it is not necessary to collect
UNWELL samples.
251
Technique for collecting saliva
1. Do not take samples for up to one hour after taking food or brushing
your teeth.(E.g. take the morning sample before breakfast, and the 5p.m.
sample before tea).
2. Rinse your mouth out with water for 20 or 30 seconds and empty your
mouth.
3. Spit directly into the tube and fill the tube up to the mark on the tube
(labelled 2.5ml). This may take a few minutes and several "spits".
4. Close the tube tightly and place the tube into the plastic bag provided
and place the bag into the freezer.
5. Repeat this for each sample, putting the tube into the same bag each
time.
6. Once all 6 samples have been collected and frozen, take them to school
as soon as possible and give them to your teacher.
Dr. John Schulga, Research Fellow in Paediatric Endocrinology,
R.H.S.C., Yorkhill, Glasgow.
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Appendix 4. Protocol for Capillary Blood Spot Testing






- 8.00a.m. next day.
2. Wash hands in warm water a few minutes before finger pricking since
warmth increases blood flow to the skin. Dry thoroughly since any
dampness on the skin may affect the blood results.
3. Some children find that a prick on the side of the finger is less painful
than on the finger pulp.
4. After pricking the finger don't squeeze it immediately but wait 10
seconds or so. Then squeeze from the base of the finger towards the
prick - don't squeeze around the prick itself since this can actually stop
the blood coming out!
5. One good drop of blood is usually enough to fill one circle.
6. Ensure that the blood soaks right through the paper to the other side
and is not just smeared on one side of the paper.
7. Soak the blood on one side of the paper only (not a bit on one side
and then a bit more on the other!).
8. Don't add extra blood to the spots after it has dried to make it bigger -
if possible try to get one large drop from the finger before putting it on
the paper so the spot does not have to be added to at all.
9. One circle filled with blood is sufficient to do the test, but if you can fill
the second circle from the same finger prick this will help the
laboratory.
10. Before putting the filter paper back in the envelope, let the blood dry.
Once this has happened the blood spots won't "go off' for weeks
provided that the strip is kept out of direct sunlight, in a dry place and
at ordinary room temperature.
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Appendix 5. Protocol for Low dose Synacthen Test
PROTOCOL FOR LOW DOSE SYNACTHEN
TEST
1. Patient must be fasted overnight.
2. Calculate the dose of Synacthen to be given :
Give 500 ng ACTH /1.73 m2 i.v.
3. To calculate the volume of synacthen to give :
250 pg ACTH in 1 ml.
Dilute to 10 ml with saline = 25 pg in 1 ml.
Dilute 1 ml of this solution to 5 ml = 5000 ng in 1 ml.
Dilute 1 ml of this solution to 10 ml = 500 ng in 1 ml.
E.g. If the patient has a body surface area of 1.73m2, the volume of
solution to give will be 1ml i.v of this solution.
4. Take a basal venous blood sample (2ml volume) - time 0.
Give ACTH as calculated.






(Peak rise in Cortisol occurs at around 15 mins. in 80% of patients)
c.f. S. Crowley et al.





Date of Birth :
DAILY ACTIVITIES RECORD (WELL)
1. Please make a note of what you were doing and how you felt for the
hour before the sample was taken.
2. Please do not take samples for at least one hour after eating food or
after brushing your teeth.
3. Remember to rinse your mouth with water before taking samples of
saliva.
4. Please take samples of saliva before taking samples of blood.
5. Please put the samples of saliva into your freezer as soon as they
have been taken.
TIME OF WAKENING : DATE :











For recording how you feel when you are not well.
Take samples if : you feel ill and have to stay in
bed.
you have a temperature of 38.5 C
or over.
1. Please make a note of what you were doing and how you felt for the
hour before the sample was taken.
2. Please do not take samples for at least one hour after eating food or
after brushing your teeth.
3. Remember to rinse your mouth with water before taking samples of
saliva.
4. Please take samples of saliva before taking samples of blood.
5. Please put the samples of saliva into your freezer as soon as they
have been taken.
TIME OF WAKENING : DATE :












Appendix 8. Protocol for single dose oral 3 day
urinary metyrapone test




Urine is collected in containers containing no
preservative.
1 collection is taken for 24 hours prior to taking
metyrapone (8a.m. to 8a.m.)
2 collections 24 hours each after taking metyrapone.
Metyrapone is taken at 8a.m. on day 2.
Assay:
Urinary steroid profiles using Gas-Liquid
chromatography.
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Appendix 9. Instructions for collecting urine for
single dose oral 3 day Metyrapone test
Instructions for collecting Urine Samples for the 3
day Metyrapone Test
1. Collect urine in the container provided (labelled Number 1) over 24 hours.
Start at a set time in the morning, preferably 8a.m.
Do not collect the first urine you pass in the morning.
(When you wake in the morning, pass urine normally in the toilet.
Start collecting your urine from then on.)
When you wake up the following morning, collect this first sample of
urine as part of the first 24 hour collection.
2. Take the capsule(s) provided as soon as you have finished the first 24-
hour urine collection.
3. Collect urine for a further 24 hours in the container labelled Number 2,
finishing this collection at 8a.m. the following morning.
4. Collect a final 24 hours of urine in the container labelled Number 3,
starting as soon as the previous collection has been completed, and
finishing at 8a.m. the following morning.
5. Take all three containers to the Biochemistry lab. with the form provided.
Day 1- urine collection No. 1. Day 2- urine collection No. 2. Day 3- urine collection No. 3.
£
First morning sample - discard
8-























First morning sample of next day
(Day 4)
Dr. John Schulga.
Research Fellow in Paediatric Endocrinology.
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Appendix 10. Insulin Tolerance Test
(Taken from Endocrine guidelines and Investigations, Royal Hospital
for Sick Children Glasgow, by Malcolm Donaldson 1996)
This is the gold standard for assessing the ability of the axis to secrete
growth hormone. Insulin hypoglycaemia also tests the adrenal axis in a more
"physiological" way than the synacthen test. In our hands the ITT is rarely
performed in isolation, and is usually combined with a LHRH and TRH test.
(i) The children will be asked to attend at 8.30 - 9.00 am having had
nothing to eat or drink (including water) since midnight. Prepubertal children
(males and females aged 10 years and over) should be primed with
stilboestrol 1 mg twice daily for three days prior to the test. The rationale of
this is to "butter up" the hypothalamus, thus enhancing its willingness to
stimulate growth hormone release from the pituitary. Please confirm that the
child has been fasting, and that he/she has been correctly primed if
appropriate. If the child has not been fasted the ITT should not be carried out,
and the test rebooked. If the child has not been primed, the test should still
go ahead. The weight and height should always be recorded.
(ii) Insert i.v and draw the -30' ("stressed") level. The GH level at this time is
important because if stress provokes GH secretion there may follow a
refractory period with no GH release in response to insulin. In these cases
the initially high GH level confirms adequate GH secretion despite
inadequate response to insulin hypoglycaemia.
(iii) Between times -30' and 0' label all bottles clearly and carefully read
the case sheet so that you fully understand the clinical problem.
(iv) If fasting glucose stix is greater than 2.2 mmol/l proceed with insulin
administration using the following doses:
0.15 u/ Kg for children 4 years and over
0.10 u/Kg for children under 4 years.
When there is a high probability of pituitary failure, the doctor arranging the
ITT will request a dose of 0.10 u/Kg to be given (check letter).
259
If initial glucose stix is less than 2.2 mmol/l await formal blood glucose and if
this confirms hypoglycaemia perform arginine test, giving i.v. synacthen
simultaneously to assess the hypothalamo-pituitary-adrenal axis.
(v) Make up the insulin solution by adding 20 units (0.2 ml) of velosulin to 20
ml saline in a syringe, thus achieving a concentration of 1U/ml.
(vi) At time 0' take further blood samples, then give the insulin (and where
appropriate other releasing hormones).
(vii) Check that there is adequate hypoglycaemia in every patient who has an
ITT. This means a fall of 50% or more from the fasting blood glucose level, or
a minimum level of 2.2 mmol/l.
Do check this by performing glucose stix checks on the sample, and if an
adequate fall of blood glucose is not obtained repeat the IV insulin in the
dosage of 0.1 U/Kg.
(viii) The procedure for management of hypoglycaemia has already been
outlined, but since the achievement of hypoglycaemia is the specific aim of
the insulin tolerance test, more detail is given here.
Most patients become drowsy, pale, quiet and sweaty with hypoglycaemia.
The nurse or parents should ensure that this child remains conscious during
the test, and the child should not be allowed to fall asleep. If glucose stix falls
to below 2.2 mmol/l, 10 ml/Kg of Lucozade will alleviate symptoms without
affecting GH secretion. If there are profound symptoms of hypoglycaemia
including difficulty being roused or trembling, give 50% dextrose (not 10), in
the dosage of 0.5g/Kg, i.e. 1 ml/Kg and repeat if necessary to raise glucostix
above 4 mmol/l. Do not discontinue sampling if glucose has to be given. Give
hydrocortisone phosphate 100 mg if the child remains unwell after glucose
administration.
After giving the 50% dextrose and hydrocortisone, re-check the glucose stix,
and do not give more dextrose unless the value is still below 6 mmol/l.
Remember that the hypoglycaemia will not cause death if you act
appropriately. It is over enthusiastic correction of hypoglycaemia with
hypotonic or hypertonic dextrose that is dangerous, and has contributed to
fatalities in children undergoing ITT's.
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Protocol for Insulin Tolerance test
Time -30 0 15 30 60 90 120
(mins)
Glucose + + + + + + +
Growth hormone + + + + + + +
Cortisol + + + + + +
Thyroxine +
TSH + + +
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